e10vq
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2009
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number: 001-16783
VCA Antech, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
95-4097995
(I.R.S. Employer
Identification No.) |
12401 West Olympic Boulevard
Los Angeles, California 90064-1022
(Address of principal executive offices)
(310) 571-6500
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o.
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files).
(Not yet applicable to the registrant)
Yes o No o.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated
filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.:
|
|
|
|
|
|
|
Large accelerated filer þ
|
|
Accelerated filer o
|
|
Non-accelerated filer o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company o |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).
Yes o No þ.
Indicate the number of shares outstanding of each of the issuers classes of common stock, as
of the latest practicable date: common stock, $0.001 par value, 85,478,182 shares as of
November 2, 2009.
VCA Antech, Inc.
Form 10-Q
September 30, 2009
Table of Contents
PART
I. FINANCIAL INFORMATION
|
|
|
ITEM 1. |
|
FINANCIAL STATEMENTS |
VCA Antech, Inc. and Subsidiaries
Condensed, Consolidated Balance Sheets
(Unaudited)
(In thousands, except par value)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
Assets
|
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
155,001 |
|
|
$ |
88,959 |
|
Trade accounts receivable, less allowance for uncollectible accounts of $12,813
and $11,025 at September 30, 2009 and December 31, 2008, respectively |
|
|
49,439 |
|
|
|
43,453 |
|
Inventory |
|
|
31,100 |
|
|
|
26,631 |
|
Prepaid expenses and other |
|
|
20,671 |
|
|
|
18,800 |
|
Deferred income taxes |
|
|
17,364 |
|
|
|
15,938 |
|
Prepaid income taxes |
|
|
1,152 |
|
|
|
5,287 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
274,727 |
|
|
|
199,068 |
|
Property and equipment, less accumulated depreciation and amortization of $159,141
and $138,431 at September 30, 2009 and December 31, 2008, respectively |
|
|
283,457 |
|
|
|
263,443 |
|
Goodwill |
|
|
970,274 |
|
|
|
922,057 |
|
Other intangible assets, net |
|
|
44,211 |
|
|
|
35,645 |
|
Notes receivable, net |
|
|
4,819 |
|
|
|
12,893 |
|
Deferred financing costs, net |
|
|
704 |
|
|
|
1,067 |
|
Other |
|
|
21,586 |
|
|
|
14,865 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
1,599,778 |
|
|
$ |
1,449,038 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Equity
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Current portion of long-term obligations |
|
$ |
8,418 |
|
|
$ |
7,771 |
|
Accounts payable |
|
|
28,958 |
|
|
|
26,087 |
|
Accrued payroll and related liabilities |
|
|
37,026 |
|
|
|
42,840 |
|
Other accrued liabilities |
|
|
48,291 |
|
|
|
46,424 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
122,693 |
|
|
|
123,122 |
|
Long-term obligations, less current portion |
|
|
538,663 |
|
|
|
544,860 |
|
Deferred income taxes |
|
|
67,560 |
|
|
|
47,331 |
|
Other liabilities |
|
|
10,525 |
|
|
|
9,890 |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
739,441 |
|
|
|
725,203 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies: |
|
|
|
|
|
|
|
|
Preferred stock, par value $0.001, 11,000 shares authorized, none outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VCA Antech, Inc. stockholders equity: |
|
|
|
|
|
|
|
|
Common stock, par value $0.001, 175,000 shares authorized, 85,441 and 84,633
shares outstanding as of September 30, 2009 and December 31, 2008, respectively |
|
|
85 |
|
|
|
85 |
|
Additional paid-in capital |
|
|
330,549 |
|
|
|
308,674 |
|
Accumulated earnings |
|
|
514,658 |
|
|
|
408,582 |
|
Accumulated other comprehensive loss |
|
|
(1,482 |
) |
|
|
(6,352 |
) |
|
|
|
|
|
|
|
Total VCA Antech, Inc. stockholders equity |
|
|
843,810 |
|
|
|
710,989 |
|
Noncontrolling interest |
|
|
16,527 |
|
|
|
12,846 |
|
|
|
|
|
|
|
|
Total equity |
|
|
860,337 |
|
|
|
723,835 |
|
|
|
|
|
|
|
|
Total liabilities and equity |
|
$ |
1,599,778 |
|
|
$ |
1,449,038 |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed, consolidated financial statements.
1
VCA Antech, Inc. and Subsidiaries
Condensed, Consolidated Income Statements
(Unaudited)
(In thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
2009 |
|
|
2008 |
|
Revenue |
|
$ |
338,562 |
|
|
$ |
332,035 |
|
|
$ |
999,288 |
|
|
$ |
974,301 |
|
Direct costs |
|
|
247,422 |
|
|
|
243,267 |
|
|
|
728,095 |
|
|
|
705,536 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
91,140 |
|
|
|
88,768 |
|
|
|
271,193 |
|
|
|
268,765 |
|
Selling, general and administrative expense |
|
|
25,258 |
|
|
|
22,003 |
|
|
|
71,652 |
|
|
|
67,990 |
|
Write-off of internal-use software |
|
|
|
|
|
|
|
|
|
|
5,271 |
|
|
|
|
|
Net loss on sale and disposal of assets |
|
|
409 |
|
|
|
90 |
|
|
|
333 |
|
|
|
33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
65,473 |
|
|
|
66,675 |
|
|
|
193,937 |
|
|
|
200,742 |
|
Interest expense, net |
|
|
4,808 |
|
|
|
6,709 |
|
|
|
16,652 |
|
|
|
21,369 |
|
Other (income) expense |
|
|
(1 |
) |
|
|
88 |
|
|
|
(131 |
) |
|
|
(44 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income taxes |
|
|
60,666 |
|
|
|
59,878 |
|
|
|
177,416 |
|
|
|
179,417 |
|
Provision for income taxes |
|
|
23,180 |
|
|
|
23,000 |
|
|
|
68,081 |
|
|
|
68,979 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
37,486 |
|
|
|
36,878 |
|
|
|
109,335 |
|
|
|
110,438 |
|
Net income attributable to noncontrolling interests |
|
|
1,125 |
|
|
|
1,104 |
|
|
|
3,259 |
|
|
|
3,145 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to VCA Antech, Inc. |
|
$ |
36,361 |
|
|
$ |
35,774 |
|
|
$ |
106,076 |
|
|
$ |
107,293 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share |
|
$ |
0.43 |
|
|
$ |
0.42 |
|
|
$ |
1.25 |
|
|
$ |
1.27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
$ |
0.42 |
|
|
$ |
0.42 |
|
|
$ |
1.23 |
|
|
$ |
1.25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding
for basic earnings per share |
|
|
85,217 |
|
|
|
84,463 |
|
|
|
84,909 |
|
|
|
84,394 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding
for diluted earnings per share |
|
|
86,431 |
|
|
|
85,789 |
|
|
|
85,893 |
|
|
|
85,789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed, consolidated financial statements.
2
VCA Antech, Inc. and Subsidiaries
Condensed, Consolidated Statements of Equity
(Unaudited)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Other |
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Comprehensive |
|
|
Noncontrolling |
|
|
|
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Earnings |
|
|
(Loss) Income |
|
|
Interest |
|
|
Total |
|
Balances, December 31, 2007 |
|
|
84,335 |
|
|
$ |
84 |
|
|
$ |
296,037 |
|
|
$ |
275,598 |
|
|
$ |
(3,335 |
) |
|
$ |
10,207 |
|
|
$ |
578,591 |
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
107,293 |
|
|
|
|
|
|
|
3,145 |
|
|
|
110,438 |
|
Foreign currency translation
adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(224 |
) |
|
|
|
|
|
|
(224 |
) |
Unrealized loss on foreign currency,
net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(92 |
) |
|
|
|
|
|
|
(92 |
) |
Unrealized loss on hedging
instruments, net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,175 |
) |
|
|
|
|
|
|
(1,175 |
) |
Losses on hedging instruments
reclassified to income, net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,461 |
|
|
|
|
|
|
|
2,461 |
|
Formation of noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,241 |
|
|
|
3,241 |
|
Distribution to noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,797 |
) |
|
|
(2,797 |
) |
Purchase of noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(374 |
) |
|
|
(374 |
) |
Share-based compensation |
|
|
|
|
|
|
|
|
|
|
5,309 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,309 |
|
Stock option activity and awards |
|
|
296 |
|
|
|
1 |
|
|
|
3,574 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,575 |
|
Tax benefit from stock options and
awards |
|
|
|
|
|
|
|
|
|
|
1,846 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,846 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances, September 30, 2008 |
|
|
84,631 |
|
|
$ |
85 |
|
|
$ |
306,766 |
|
|
$ |
382,891 |
|
|
$ |
(2,365 |
) |
|
$ |
13,422 |
|
|
$ |
700,799 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances, December 31, 2008 |
|
|
84,633 |
|
|
$ |
85 |
|
|
$ |
308,674 |
|
|
$ |
408,582 |
|
|
$ |
(6,352 |
) |
|
$ |
12,846 |
|
|
$ |
723,835 |
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
106,076 |
|
|
|
|
|
|
|
3,259 |
|
|
|
109,335 |
|
Foreign currency translation
adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
592 |
|
|
|
|
|
|
|
592 |
|
Unrealized gain on foreign currency,
net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
288 |
|
|
|
|
|
|
|
288 |
|
Unrealized loss on hedging
instruments, net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(801 |
) |
|
|
|
|
|
|
(801 |
) |
Losses on hedging instruments
reclassified to income, net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,791 |
|
|
|
|
|
|
|
4,791 |
|
Formation of noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,440 |
|
|
|
3,440 |
|
Distribution to noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,018 |
) |
|
|
(3,018 |
) |
Restricted stock unit grant |
|
|
|
|
|
|
|
|
|
|
1,941 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,941 |
|
Share-based compensation |
|
|
|
|
|
|
|
|
|
|
5,940 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,940 |
|
Stock option activity and awards |
|
|
808 |
|
|
|
|
|
|
|
13,110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,110 |
|
Stock repurchases |
|
|
|
|
|
|
|
|
|
|
(561 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(561 |
) |
Tax benefit from stock options and
awards |
|
|
|
|
|
|
|
|
|
|
1,445 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,445 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances, September 30, 2009 |
|
|
85,441 |
|
|
$ |
85 |
|
|
$ |
330,549 |
|
|
$ |
514,658 |
|
|
$ |
(1,482 |
) |
|
$ |
16,527 |
|
|
$ |
860,337 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed, consolidated financial statements.
3
VCA Antech, Inc. and Subsidiaries
Condensed, Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
109,335 |
|
|
$ |
110,438 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
28,986 |
|
|
|
23,762 |
|
Amortization of debt issue costs |
|
|
363 |
|
|
|
351 |
|
Provision for uncollectible accounts |
|
|
5,075 |
|
|
|
3,671 |
|
Net loss on sale and disposal of assets |
|
|
333 |
|
|
|
33 |
|
Share-based compensation |
|
|
5,940 |
|
|
|
5,309 |
|
Deferred income taxes |
|
|
16,057 |
|
|
|
9,894 |
|
Excess tax benefit from exercise of stock options |
|
|
(591 |
) |
|
|
(1,846 |
) |
Write-off of internal-use software |
|
|
5,271 |
|
|
|
|
|
Other |
|
|
(299 |
) |
|
|
192 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(8,312 |
) |
|
|
(5,736 |
) |
Inventory, prepaid expenses and other assets |
|
|
(7,820 |
) |
|
|
(5,972 |
) |
Accounts payable and other accrued liabilities |
|
|
742 |
|
|
|
(438 |
) |
Accrued payroll and related liabilities |
|
|
(4,339 |
) |
|
|
(3,553 |
) |
Income taxes |
|
|
5,580 |
|
|
|
9,457 |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
156,321 |
|
|
|
145,562 |
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Business acquisitions, net of cash acquired |
|
|
(51,853 |
) |
|
|
(89,775 |
) |
Real estate acquired in connection with business acquisitions |
|
|
(3,828 |
) |
|
|
(15,063 |
) |
Property and equipment additions |
|
|
(38,522 |
) |
|
|
(39,764 |
) |
Proceeds from sale of assets |
|
|
123 |
|
|
|
1,774 |
|
Other |
|
|
(440 |
) |
|
|
(15,024 |
) |
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(94,520 |
) |
|
|
(157,852 |
) |
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Repayment of long-term obligations |
|
|
(5,898 |
) |
|
|
(5,852 |
) |
Distributions to noncontrolling interest partners |
|
|
(3,018 |
) |
|
|
(2,797 |
) |
Proceeds from issuance of common stock under stock option plans |
|
|
13,110 |
|
|
|
3,574 |
|
Excess tax benefit from exercise of stock options |
|
|
591 |
|
|
|
1,846 |
|
Stock repurchases |
|
|
(561 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities |
|
|
4,224 |
|
|
|
(3,229 |
) |
|
|
|
|
|
|
|
Effect of currency exchange rate changes on cash and cash equivalents |
|
|
17 |
|
|
|
(44 |
) |
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents |
|
|
66,042 |
|
|
|
(15,563 |
) |
Cash and cash equivalents at beginning of period |
|
|
88,959 |
|
|
|
110,866 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
155,001 |
|
|
$ |
95,303 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information: |
|
|
|
|
|
|
|
|
Interest paid |
|
$ |
16,329 |
|
|
$ |
23,449 |
|
Income taxes paid |
|
$ |
46,444 |
|
|
$ |
49,628 |
|
|
|
|
|
|
|
|
|
|
Supplemental schedule of non-cash investing and financing activities: |
|
|
|
|
|
|
|
|
Detail of acquisitions: |
|
|
|
|
|
|
|
|
Fair value of assets acquired |
|
$ |
72,303 |
|
|
$ |
92,930 |
|
Cash paid for acquisitions |
|
|
(48,042 |
) |
|
|
(88,136 |
) |
Non-cash note conversion to equity interest in subsidiary |
|
|
(5,700 |
) |
|
|
|
|
Contingent consideration |
|
|
(712 |
) |
|
|
|
|
|
|
|
|
|
|
|
Liabilities assumed |
|
$ |
17,849 |
|
|
$ |
4,794 |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed, consolidated financial statements.
4
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements
September 30, 2009
(Unaudited)
1. Nature of Operations
Our company, VCA Antech, Inc. (VCA) is a Delaware corporation formed in 1986 and is based in
Los Angeles, California. We are an animal healthcare company with three strategic segments: animal
hospitals (Animal Hospital), veterinary diagnostic laboratories (Laboratory) and veterinary
medical technology (Medical Technology).
Our animal hospitals offer a full range of general medical and surgical services for companion
animals. Our animal hospitals treat diseases and injuries, provide pharmaceutical products and
perform a variety of pet-wellness programs, including health examinations, diagnostic testing,
vaccinations, spaying, neutering and dental care. At September 30, 2009, we operated 482 animal
hospitals throughout 40 states.
We operate a full-service veterinary diagnostic laboratory network serving all 50 states and
certain areas in Canada. Our laboratory network provides sophisticated testing and consulting
services used by veterinarians in the detection, diagnosis, evaluation, monitoring, treatment and
prevention of diseases and other conditions affecting animals. At September 30, 2009, we operated
46 laboratories of various sizes located strategically throughout the United States and Canada.
Our Medical Technology segment sells digital radiography and ultrasound imaging equipment,
provides education and training on the use of that equipment, provides consulting and mobile
imaging services, and sells software and ancillary services to the veterinary
market.
2. Basis of Presentation
Our accompanying unaudited, condensed, consolidated financial statements have been prepared in
accordance with generally accepted accounting principles in the United States (GAAP) for interim
financial information and in accordance with the rules and regulations of the United States
Securities and Exchange Commission (SEC). Accordingly, they do not include all of the
information and notes required by GAAP for annual financial statements as permitted under
applicable rules and regulations. In the opinion of management, all normal recurring adjustments
considered necessary for a fair presentation have been included. Certain reclassifications have
been made herein to 2008 amounts to conform to the current year presentation. These include the
adoption of the Financial Accounting Standards Boards (FASB) new accounting guidance on
noncontrolling interests in consolidated financial statements. The results of operations for the
three and nine months ended September 30, 2009 are not necessarily indicative of the results to be
expected for the full year ending December 31, 2009. For further information, refer to our
consolidated financial statements and notes thereto included in our 2008 Annual Report on Form
10-K.
In June 2009, the FASB issued the FASB Accounting Standards Codification (Codification) as
the single source of GAAP. The Codification was effective for our company beginning July 1, 2009.
The Codification does not change GAAP and did not impact our consolidated financial statements.
The preparation of our condensed, consolidated financial statements in accordance with GAAP
requires management to make estimates and assumptions that affect the amounts reported in our
condensed, consolidated financial statements and notes thereto. Actual results could differ from
those estimates.
We evaluated the effects of all subsequent events through November 6, 2009, the date this
report is filed with the SEC.
3. Goodwill and Other Intangible Assets
In April 2008, the FASB issued new accounting guidance on the determination of the useful life
of intangible assets. The guidance was designed to improve the consistency between the useful life
of a recognized intangible asset under previous guidance related to goodwill and other intangible
assets and the period of expected cash flows used to measure the fair value of the asset under
business combinations guidance, and other GAAP. We adopted the
5
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
3. Goodwill and Other Intangible Assets, continued
new guidance on January 1, 2009. The adoption did not have a material impact on our consolidated
financial statements.
Goodwill
Goodwill represents the excess of the aggregate of the consideration transferred, the fair
value of any noncontrolling interest in the acquiree and for a business combination achieved in
stages, the acquisition-date fair value of any previously held equity interest over the net of the
fair value of identifiable assets acquired and liabilities assumed. The following table presents
the changes in the carrying amount of our goodwill for the nine months ended September 30, 2009 (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal |
|
|
|
|
|
|
Medical |
|
|
|
|
|
|
Hospital |
|
|
Laboratory |
|
|
Technology |
|
|
Total |
|
Balance as of December 31, 2008 |
|
$ |
807,203 |
|
|
$ |
95,694 |
|
|
$ |
19,160 |
|
|
$ |
922,057 |
|
Goodwill acquired |
|
|
32,484 |
|
|
|
430 |
|
|
|
11,127 |
|
|
|
44,041 |
|
Goodwill related to noncontrolling interests |
|
|
3,440 |
|
|
|
|
|
|
|
|
|
|
|
3,440 |
|
Other (1) |
|
|
583 |
|
|
|
153 |
|
|
|
|
|
|
|
736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of September 30, 2009 |
|
$ |
843,710 |
|
|
$ |
96,277 |
|
|
$ |
30,287 |
|
|
$ |
970,274 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Other includes purchase-price adjustments, buy-outs, earn-out payments and currency
translation adjustments. |
Other Intangible Assets
In addition to goodwill, we have amortizable intangible assets at September 30, 2009 and
December 31, 2008 as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2009 |
|
|
As of December 31, 2008 |
|
|
|
Gross |
|
|
|
|
|
|
Net |
|
|
Gross |
|
|
|
|
|
|
Net |
|
|
|
Carrying |
|
|
Accumulated |
|
|
Carrying |
|
|
Carrying |
|
|
Accumulated |
|
|
Carrying |
|
|
|
Amount |
|
|
Amortization |
|
|
Amount |
|
|
Amount |
|
|
Amortization |
|
|
Amount |
|
Noncontractual customer
relationships |
|
$ |
36,268 |
|
|
$ |
(6,817 |
) |
|
$ |
29,451 |
|
|
$ |
26,412 |
|
|
$ |
(3,689 |
) |
|
$ |
22,723 |
|
Covenants not-to-compete |
|
|
14,532 |
|
|
|
(7,335 |
) |
|
|
7,197 |
|
|
|
16,195 |
|
|
|
(8,001 |
) |
|
|
8,194 |
|
Favorable lease asset |
|
|
4,119 |
|
|
|
(431 |
) |
|
|
3,688 |
|
|
|
4,689 |
|
|
|
(629 |
) |
|
|
4,060 |
|
Trademarks |
|
|
3,316 |
|
|
|
(395 |
) |
|
|
2,921 |
|
|
|
699 |
|
|
|
(251 |
) |
|
|
448 |
|
Technology |
|
|
2,209 |
|
|
|
(1,297 |
) |
|
|
912 |
|
|
|
1,270 |
|
|
|
(1,076 |
) |
|
|
194 |
|
Client lists |
|
|
103 |
|
|
|
(61 |
) |
|
|
42 |
|
|
|
84 |
|
|
|
(58 |
) |
|
|
26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
60,547 |
|
|
$ |
(16,336 |
) |
|
$ |
44,211 |
|
|
$ |
49,349 |
|
|
$ |
(13,704 |
) |
|
$ |
35,645 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table summarizes our aggregate amortization expense related to other intangible
assets (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
2009 |
|
|
2008 |
|
Aggregate amortization expense |
|
$ |
2,013 |
|
|
$ |
1,792 |
|
|
$ |
5,643 |
|
|
$ |
4,739 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
3. Goodwill and Other Intangible Assets, continued
The estimated amortization expense related to intangible assets for the remainder of fiscal
2009 and each of the succeeding years thereafter as of September 30, 2009 is as follows (in
thousands):
|
|
|
|
|
Remainder of 2009 |
|
$ |
2,155 |
|
2010 |
|
|
8,321 |
|
2011 |
|
|
7,477 |
|
2012 |
|
|
6,511 |
|
2013 |
|
|
5,354 |
|
Thereafter |
|
|
13,942 |
|
|
|
|
|
Total (1) |
|
$ |
43,760 |
|
|
|
|
|
|
|
|
(1) |
|
This excludes $451,000 of intangible assets that are not subject to amortization. |
4. Noncontrolling Interests
Effective
January 1, 2009, we adopted the new accounting guidance for noncontrolling interests
on a retrospective basis. The new guidance changes the accounting and reporting for minority
interests which have been recharacterized as noncontrolling interests and are now classified as a
component of equity in our condensed, consolidated balance sheets. The adoption also resulted in
new presentation and disclosure requirements for noncontrolling interests within our condensed,
consolidated income statements, statements of equity and statements of cash flows. The adoption
did not have a material impact on our consolidated financial statements.
5. Other Accrued Liabilities
Other accrued liabilities consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
Accrued workers compensation insurance |
|
$ |
3,934 |
|
|
$ |
4,436 |
|
Deferred revenue |
|
|
11,397 |
|
|
|
7,303 |
|
Interest rate swap liability |
|
|
2,278 |
|
|
|
8,899 |
|
Other |
|
|
30,682 |
|
|
|
25,786 |
|
|
|
|
|
|
|
|
|
|
$ |
48,291 |
|
|
$ |
46,424 |
|
|
|
|
|
|
|
|
6. Interest Rate Swap Agreements
In March 2008, the FASB issued new accounting guidance on disclosure requirements for
derivative instruments and hedging activities to enhance the current disclosure framework. The
additional disclosures require information about how our interest rate swap agreements and hedging
activities affect our financial position, financial performance, and cash flows. We adopted the
new guidance on January 1, 2009 and have included the applicable disclosures below and in Note 7.
The adoption did not have a material impact on our consolidated financial statements.
In accordance with current accounting guidance, all investments in derivatives are recorded at
fair value. A derivative is typically defined as an instrument whose value is derived from an
underlying instrument, index or rate, has a notional amount, requires little or no initial
investment and can be net settled. Our derivatives are reported as current assets and liabilities
or other non-current assets or liabilities as appropriate.
7
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
6. Interest Rate Swap Agreements, continued
We use interest rate swap agreements to mitigate our exposure to increasing interest rates as
well as to maintain an appropriate mix of fixed-rate and variable-rate debt.
If we determine that contracts are effective at meeting our risk reduction and correlation
criteria we account for them using hedge accounting. Under hedge accounting, we recognize the
effective portion of changes in the fair value of the contracts in other comprehensive income and
the ineffective portion in earnings. If we determine that contracts do not, or no longer, meet our
risk reduction and correlation criteria, we account for them under a fair-value method recognizing
changes in the fair value in earnings in the period of change. If we determine that a contract no
longer meets our risk reduction and correlation criteria, or if the derivative expires, we
recognize in earnings any accumulated balance in other comprehensive income related to the contract
in the period of determination. For interest rate swap agreements accounted for under hedge
accounting, we assess the effectiveness based on changes in their intrinsic value with changes in
the time value portion of the contract reflected in earnings. All cash payments made or received
under the contracts are recognized in interest expense.
Credit exposure associated with non-performance by the counterparties to derivative
instruments is generally limited to the uncollateralized fair value of the asset related to
instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of
non-performance by selecting counterparties with high credit ratings and monitoring their
creditworthiness and by diversifying derivative amounts with multiple counterparties.
The contractual or notional amounts for derivatives are used to calculate the exchange of
contractual payments under the agreements and are not representative of the potential for gain or
loss on these instruments. Interest rates affect the fair value of derivatives. The fair values
generally represent the estimated amounts that we would expect to receive or pay upon termination
of the contracts at the reporting date. The fair values are based upon dealer quotes when
available or an estimate using values obtained from independent pricing services, costs to settle
or quoted market prices of comparable instruments.
We have entered into interest rate swap agreements whereby we pay to the counterparties
amounts based on fixed interest rates and set notional principal amounts in exchange for the
receipt of payments from counterparties based on current London Interbank Offer Rates (LIBOR) and
the same set notional principal amounts. The purpose of these hedges is to offset the variability
of cash flows due to our outstanding variable-rate debt under our senior-term notes. A summary of
these agreements is as follows:
|
|
|
|
|
|
|
|
|
|
|
Interest Rate Swap Agreements |
Fixed interest rate |
|
|
5.34% |
|
|
|
2.64% |
|
Notional amount (in millions) |
|
|
$ 100.0 |
|
|
|
$ 100.0 |
|
Effective date |
|
|
6/11/2007 |
|
|
|
2/12/2008 |
|
Expiration date |
|
|
12/31/2009 |
|
|
|
2/26/2010 |
|
Counterparty |
|
Goldman Sachs |
|
|
Wells Fargo |
|
Qualifies for hedge accounting |
|
Yes |
|
Yes |
The following table summarizes cash received or cash paid and ineffectiveness reported in
earnings as a result of our interest rate swap agreements (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
2009 |
|
|
2008 |
|
Cash paid (1) |
|
$ |
1,895 |
|
|
$ |
1,639 |
|
|
$ |
7,867 |
|
|
$ |
4,030 |
|
Recognized loss (gain) from ineffectiveness (2) |
|
$ |
1 |
|
|
$ |
12 |
|
|
$ |
(70 |
) |
|
$ |
(24 |
) |
|
|
|
(1) |
|
Our interest rate swap agreements effectively convert a certain amount of our variable-rate
debt under our senior credit facility to fixed-rate debt in an attempt to mitigate interest
rate risk. The above table depicts both cash payments to and receipts from the counterparties
on our swap agreements. These payments and receipts are offset by a corresponding decrease or
increase in interest paid on our variable-rate debt under our senior credit facility. |
8
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
6. Interest Rate Swap Agreements, continued
|
|
|
(2) |
|
These recognized losses and gains are included in other income in our condensed, consolidated
income statements. |
7. Fair Value Measurements
On January 1, 2008, we adopted the applicable provisions of the new accounting guidance on
fair value measurements which defines fair value, establishes a framework for measuring fair value
and expands disclosures about fair value measurements related to financial instruments. On January
1, 2009, we adopted the new guidance for our non-financial assets and non-financial liabilities
measured on a non-recurring basis. As of September 30, 2009, we do not have any applicable
non-recurring measurements of non-financial assets and non-financial liabilities.
Current fair value accounting guidance includes a hierarchy that is intended to increase
consistency and comparability in fair value measurements and related disclosures. The fair value
hierarchy is based on inputs to valuation techniques that are used to measure fair value that are
either observable or unobservable. Observable inputs reflect assumptions market participants would
use in pricing an asset or liability based on market data obtained from independent sources while
unobservable inputs reflect a reporting entitys pricing based upon their own market assumptions.
The current guidance establishes a three-tiered fair value hierarchy which prioritizes the inputs
used in measuring fair value as follows:
|
|
|
Level 1. Observable inputs such as quoted prices in active markets; |
|
|
|
|
Level 2. Inputs, other than quoted prices, that are observable for the asset or
liability, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or
liabilities in markets that are not active; and |
|
|
|
|
Level 3. Unobservable inputs in which there is little or no market data, which require
the reporting entity to develop its own assumptions. |
Fair Value of Financial Instruments
In April 2009, the FASB issued new accounting guidance for disclosures about fair value of
financial instruments, which amends the previous guidance to require disclosures about fair value
of financial instruments for interim reporting periods of publicly traded companies as well as in
annual financial statements. The new guidance also amends the previous guidance related to
interim financial reporting to require those disclosures in summarized financial information at
interim reporting periods. The new guidance is effective for interim periods ending after June
15, 2009. We early adopted the provisions and all other related guidance for the quarter ended
March 31, 2009.
The Codification requires disclosure of fair value information about financial instruments,
whether or not recognized in the accompanying consolidated balance sheets. Fair value as defined
by the Codification is the price that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants at the measurement date. The fair
value estimates of financial instruments are not necessarily indicative of the amounts we might pay
or receive in actual market transactions. The use of different market assumptions and/or
estimation methodologies may have a material effect on the estimated fair value amounts.
9
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
7. Fair Value Measurements, continued
Cash and Cash Equivalents. These balances include cash and cash equivalents with maturities
of less than three months. The carrying amount approximates fair value due to the short-term
maturities of these instruments.
Receivables, Less Allowance for Doubtful Accounts, Accounts Payable and Certain Other Accrued
Liabilities. Due to their short-term nature, fair value approximates carrying value.
Long-Term Debt. We believe the carrying values of our variable-rate debt at September 30,
2009 and December 31, 2008 are not reasonable estimates of fair value due to changes in the credit
markets during 2008 and 2009. We have estimated the fair value of our variable-rate debt using
discounted cash flow techniques utilizing current market rates, which incorporate our credit risk.
The following table reflects the carrying value and fair value of our long-term debt (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2009 |
|
|
As of December 31, 2008 |
|
|
|
Carrying |
|
|
Fair |
|
|
Carrying |
|
|
Fair |
|
|
|
Value |
|
|
Value |
|
|
Value |
|
|
Value |
|
Variable-rate long-term debt |
|
$ |
518,237 |
|
|
$ |
511,912 |
|
|
$ |
522,282 |
|
|
$ |
499,025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest Rate Swap Agreements. We use the market approach to measure fair value for our
interest rate swap agreements. The market approach uses prices and other relevant information
generated by market transactions involving comparable assets or liabilities.
The following table reflects the fair value of our interest rate swap agreements, which is
measured on a recurring basis as defined by the Codification (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basis of Fair Value Measurement |
|
|
|
|
|
|
|
Quoted Prices |
|
|
Significant Other |
|
|
Significant |
|
|
|
|
|
|
|
In Active Markets |
|
|
Observable |
|
|
Unobservable |
|
|
|
|
|
|
|
for Identical Items |
|
|
Inputs |
|
|
Inputs |
|
|
|
Balance |
|
|
(Level 1) |
|
|
(Level 2) |
|
|
(Level 3) |
|
At September 30, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other accrued liabilities |
|
$ |
2,278 |
|
|
$ |
|
|
|
$ |
2,278 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other accrued liabilities |
|
$ |
8,899 |
|
|
$ |
|
|
|
$ |
8,899 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8. Share-Based Compensation
Stock Option Activity
There were no stock options granted during the nine months ended September 30, 2009. The
aggregate intrinsic value of our stock options exercised during the three and nine months ended
September 30, 2009 was $4.6 million and $5.9 million, respectively, and the actual tax benefit
realized on options exercised during these periods was $1.8 million and $2.3 million, respectively.
At September 30, 2009 there was $4.5 million of total unrecognized compensation cost related
to our stock options. This cost is expected to be recognized over a weighted-average period of 2.4
years.
10
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
8. Share-Based Compensation, continued
The compensation cost that has been charged against income for stock options for the three
months ended September 30, 2009 and 2008 was $471,000 and $418,000, respectively. The
corresponding income tax benefit recognized was $183,000 and $163,000 for the three months ended
September 30, 2009 and 2008, respectively.
The compensation cost that has been charged against income for stock options for the nine
months ended September 30, 2009 and 2008 was $1.5 million and $1.3 million, respectively. The
corresponding income tax benefit recognized was $574,000 and $503,000 for the nine months ended
September 30, 2009 and 2008, respectively.
Non-Vested Stock Activity
There were no non-vested common stock awards granted during the three months ended September
30, 2009. During the nine months ended September 30, 2009 we granted 12,096 shares of non-vested
common stock. These awards were granted to our non-employee directors and will vest in equal
annual installments over three years from the grant date.
Total compensation cost charged against income related to non-vested stock awards was $1.5
million and $1.6 million for the three months ended September 30, 2009 and 2008, respectively. The
corresponding income tax benefit recognized in the income statement was $603,000 and $611,000 for
the three months ended September 30, 2009 and 2008, respectively.
Total compensation cost charged against income related to non-vested stock awards was $4.5
million and $4.0 million for the nine months ended September 30, 2009 and 2008, respectively. The
corresponding income tax benefit recognized in the income statement was $1.7 million and $1.6
million for the nine months ended September 30, 2009 and 2008, respectively.
At September 30, 2009, there was $10.1 million of unrecognized compensation cost related to
these non-vested shares, which will be recognized over a weighted-average period of two years. A
summary of our non-vested stock activity for the nine months ended September 30, 2009 is as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
|
|
|
|
|
Average Fair |
|
|
|
|
|
|
|
Value |
|
|
|
Shares |
|
|
Per Share |
|
Outstanding at December 31, 2008 |
|
|
724,235 |
|
|
$ |
31.52 |
|
Granted |
|
|
12,096 |
|
|
$ |
24.80 |
|
Vested |
|
|
(90,660 |
) |
|
$ |
32.89 |
|
Forfeited/Canceled |
|
|
(10,875 |
) |
|
$ |
34.12 |
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2009 |
|
|
634,796 |
|
|
$ |
31.15 |
|
|
|
|
|
|
|
|
|
Restricted Stock Unit Activity
Pursuant to the terms of the 2006 Equity Incentive Plan, on April 17, 2009, we awarded 84,757
restricted stock units in lieu of cash bonuses to our four senior executive officers for services
performed in fiscal year 2008. Restricted stock units differ from the non-vested stock awards
mentioned above in that the restricted stock units were fully vested or earned by the employee on
the grant date; however, they are restricted such that the participant will not have any right,
title, or interest in, or otherwise be considered the owner of, any of the shares of common stock
covered by the restricted stock units until such shares of common stock are settled. The
restricted stock units will be settled upon the first to occur of the following: May 1, 2012, the
date of the senior executives separation from service, death or disability, or the date of a
change in control. The restricted stock units had a grant-date fair value of $22.90 per share,
resulting in a total value of $1.9 million, and the grant is considered a non-cash financing
activity in the current period.
11
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
9. Calculation of Earnings per Share
Basic earnings per share is calculated by dividing net income by the weighted-average number
of shares outstanding during the period. Diluted earnings per share is calculated by dividing net
income by the weighted-average number of common shares outstanding, after giving effect to all
dilutive potential common shares outstanding during the period. Basic and diluted earnings per
share were calculated as follows (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
2009 |
|
|
2008 |
|
Net income
attributable to VCA Antech, Inc. |
|
$ |
36,361 |
|
|
$ |
35,774 |
|
|
$ |
106,076 |
|
|
$ |
107,293 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
85,217 |
|
|
|
84,463 |
|
|
|
84,909 |
|
|
|
84,394 |
|
Effect of dilutive potential common shares: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options |
|
|
951 |
|
|
|
1,184 |
|
|
|
779 |
|
|
|
1,271 |
|
Non-vested shares |
|
|
263 |
|
|
|
142 |
|
|
|
205 |
|
|
|
124 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
86,431 |
|
|
|
85,789 |
|
|
|
85,893 |
|
|
|
85,789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share |
|
$ |
0.43 |
|
|
$ |
0.42 |
|
|
$ |
1.25 |
|
|
$ |
1.27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
$ |
0.42 |
|
|
$ |
0.42 |
|
|
$ |
1.23 |
|
|
$ |
1.25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended September 30, 2009 and 2008, potential common shares of 9,111 and
45,330, respectively, were excluded from the computation of diluted earnings per share because
their inclusion would have had an anti-dilutive effect.
For the nine months ended September 30, 2009 and 2008, potential common shares of 1,227,008
and 45,330, respectively, were excluded from the computation of diluted earnings per share because
their inclusion would have had an anti-dilutive effect.
10. Comprehensive Income
Total comprehensive income consists of net income and the other comprehensive income during
the three and nine months ended September 30, 2009 and 2008. The following table provides a
summary of comprehensive income (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
2009 |
|
|
2008 |
|
Net income |
|
$ |
37,486 |
|
|
$ |
36,878 |
|
|
$ |
109,335 |
|
|
$ |
110,438 |
|
Other comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
|
|
415 |
|
|
|
(206 |
) |
|
|
592 |
|
|
|
(224 |
) |
Unrealized gain (loss) on foreign currency |
|
|
316 |
|
|
|
(92 |
) |
|
|
473 |
|
|
|
(92 |
) |
Tax expense |
|
|
(124 |
) |
|
|
|
|
|
|
(185 |
) |
|
|
|
|
Unrealized loss on hedging instruments |
|
|
(245 |
) |
|
|
(218 |
) |
|
|
(1,315 |
) |
|
|
(1,983 |
) |
Tax benefit |
|
|
96 |
|
|
|
129 |
|
|
|
514 |
|
|
|
808 |
|
Losses on hedging instruments reclassified to income |
|
|
1,895 |
|
|
|
1,639 |
|
|
|
7,867 |
|
|
|
4,030 |
|
Tax benefit |
|
|
(741 |
) |
|
|
(639 |
) |
|
|
(3,076 |
) |
|
|
(1,569 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income |
|
|
1,612 |
|
|
|
613 |
|
|
|
4,870 |
|
|
|
970 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income |
|
|
39,098 |
|
|
|
37,491 |
|
|
|
114,205 |
|
|
|
111,408 |
|
Comprehensive income attributable to noncontrolling interests |
|
|
1,125 |
|
|
|
1,104 |
|
|
|
3,259 |
|
|
|
3,145 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
income attributable to VCA Antech, Inc. |
|
$ |
37,973 |
|
|
$ |
36,387 |
|
|
$ |
110,946 |
|
|
$ |
108,263 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
11. Lines of Business
Our reportable segments are Animal Hospital, Laboratory and Medical Technology. These
segments are strategic business units that have different services, products and/or functions. The
segments are managed separately because each is a distinct and different business venture with
unique challenges, risks and rewards. Our Animal Hospital segment provides veterinary services for
companion animals and sells related retail and pharmaceutical products. Our Laboratory segment
provides diagnostic laboratory testing services for veterinarians, both associated with our animal
hospitals and those independent of us. Our Medical Technology segment sells digital radiography
and ultrasound imaging equipment, related computer hardware, software and ancillary services to the
veterinary market. We also operate a corporate office that provides general and administrative
support services for our other segments.
The accounting policies of our segments are the same as those described in the summary of
significant accounting policies included in our 2008 Annual Report on Form 10-K. We evaluate the
performance of our segments based on gross profit and operating income. For purposes of reviewing
the operating performance of our segments all intercompany sales and purchases are generally
accounted for as if they were transactions with independent third parties at current market prices.
The following is a summary of certain financial data for each of our segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal |
|
|
|
|
|
|
Medical |
|
|
|
|
|
|
Intercompany |
|
|
|
|
|
|
Hospital |
|
|
Laboratory |
|
|
Technology |
|
|
Corporate |
|
|
Eliminations |
|
|
Total |
|
Three Months Ended September 30, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External revenue |
|
$ |
257,385 |
|
|
$ |
69,504 |
|
|
$ |
11,673 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
338,562 |
|
Intercompany revenue |
|
|
|
|
|
|
7,958 |
|
|
|
2,059 |
|
|
|
|
|
|
|
(10,017 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
257,385 |
|
|
|
77,462 |
|
|
|
13,732 |
|
|
|
|
|
|
|
(10,017 |
) |
|
|
338,562 |
|
Direct costs |
|
|
206,172 |
|
|
|
41,636 |
|
|
|
9,024 |
|
|
|
|
|
|
|
(9,410 |
) |
|
|
247,422 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
51,213 |
|
|
|
35,826 |
|
|
|
4,708 |
|
|
|
|
|
|
|
(607 |
) |
|
|
91,140 |
|
Selling, general and administrative expense |
|
|
5,162 |
|
|
|
5,621 |
|
|
|
4,316 |
|
|
|
10,159 |
|
|
|
|
|
|
|
25,258 |
|
Net loss on sale and disposal of assets |
|
|
400 |
|
|
|
1 |
|
|
|
1 |
|
|
|
7 |
|
|
|
|
|
|
|
409 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
$ |
45,651 |
|
|
$ |
30,204 |
|
|
$ |
391 |
|
|
$ |
(10,166 |
) |
|
$ |
(607 |
) |
|
$ |
65,473 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
$ |
6,777 |
|
|
$ |
2,364 |
|
|
$ |
616 |
|
|
$ |
603 |
|
|
$ |
(214 |
) |
|
$ |
10,146 |
|
Capital expenditures |
|
$ |
10,571 |
|
|
$ |
2,388 |
|
|
$ |
347 |
|
|
$ |
557 |
|
|
$ |
(549 |
) |
|
$ |
13,314 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External revenue |
|
$ |
253,251 |
|
|
$ |
69,035 |
|
|
$ |
9,749 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
332,035 |
|
Intercompany revenue |
|
|
|
|
|
|
8,030 |
|
|
|
2,797 |
|
|
|
|
|
|
|
(10,827 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
253,251 |
|
|
|
77,065 |
|
|
|
12,546 |
|
|
|
|
|
|
|
(10,827 |
) |
|
|
332,035 |
|
Direct costs |
|
|
202,965 |
|
|
|
41,792 |
|
|
|
8,224 |
|
|
|
|
|
|
|
(9,714 |
) |
|
|
243,267 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
50,286 |
|
|
|
35,273 |
|
|
|
4,322 |
|
|
|
|
|
|
|
(1,113 |
) |
|
|
88,768 |
|
Selling, general and administrative expense |
|
|
5,643 |
|
|
|
5,178 |
|
|
|
3,120 |
|
|
|
8,062 |
|
|
|
|
|
|
|
22,003 |
|
Net loss on sale and disposal of assets |
|
|
25 |
|
|
|
3 |
|
|
|
2 |
|
|
|
60 |
|
|
|
|
|
|
|
90 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
$ |
44,618 |
|
|
$ |
30,092 |
|
|
$ |
1,200 |
|
|
$ |
(8,122 |
) |
|
$ |
(1,113 |
) |
|
$ |
66,675 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
$ |
5,816 |
|
|
$ |
1,923 |
|
|
$ |
404 |
|
|
$ |
446 |
|
|
$ |
(152 |
) |
|
$ |
8,437 |
|
Capital expenditures |
|
$ |
11,327 |
|
|
$ |
2,777 |
|
|
$ |
46 |
|
|
$ |
756 |
|
|
$ |
(685 |
) |
|
$ |
14,221 |
|
13
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
11. Lines of Business, continued
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal |
|
|
|
|
|
|
Medical |
|
|
|
|
|
|
Intercompany |
|
|
|
|
|
|
Hospital |
|
|
Laboratory |
|
|
Technology |
|
|
Corporate |
|
|
Eliminations |
|
|
Total |
|
Nine Months Ended September 30, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External revenue |
|
$ |
757,030 |
|
|
$ |
213,354 |
|
|
$ |
28,904 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
999,288 |
|
Intercompany revenue |
|
|
|
|
|
|
24,408 |
|
|
|
4,614 |
|
|
|
|
|
|
|
(29,022 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
757,030 |
|
|
|
237,762 |
|
|
|
33,518 |
|
|
|
|
|
|
|
(29,022 |
) |
|
|
999,288 |
|
Direct costs |
|
|
609,520 |
|
|
|
124,900 |
|
|
|
21,452 |
|
|
|
|
|
|
|
(27,777 |
) |
|
|
728,095 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
147,510 |
|
|
|
112,862 |
|
|
|
12,066 |
|
|
|
|
|
|
|
(1,245 |
) |
|
|
271,193 |
|
Selling, general and administrative expense |
|
|
15,924 |
|
|
|
16,832 |
|
|
|
10,058 |
|
|
|
28,838 |
|
|
|
|
|
|
|
71,652 |
|
Write-off of internal-use software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,271 |
|
|
|
|
|
|
|
5,271 |
|
Net loss on sale and disposal of assets |
|
|
270 |
|
|
|
28 |
|
|
|
7 |
|
|
|
28 |
|
|
|
|
|
|
|
333 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
$ |
131,316 |
|
|
$ |
96,002 |
|
|
$ |
2,001 |
|
|
$ |
(34,137 |
) |
|
$ |
(1,245 |
) |
|
$ |
193,937 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
$ |
19,636 |
|
|
$ |
6,827 |
|
|
$ |
1,365 |
|
|
$ |
1,759 |
|
|
$ |
(601 |
) |
|
$ |
28,986 |
|
Capital expenditures |
|
$ |
29,447 |
|
|
$ |
6,506 |
|
|
$ |
665 |
|
|
$ |
3,235 |
|
|
$ |
(1,331 |
) |
|
$ |
38,522 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External revenue |
|
$ |
730,352 |
|
|
$ |
211,684 |
|
|
$ |
32,265 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
974,301 |
|
Intercompany revenue |
|
|
|
|
|
|
23,950 |
|
|
|
5,968 |
|
|
|
|
|
|
|
(29,918 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
730,352 |
|
|
|
235,634 |
|
|
|
38,233 |
|
|
|
|
|
|
|
(29,918 |
) |
|
|
974,301 |
|
Direct costs |
|
|
586,309 |
|
|
|
122,145 |
|
|
|
24,776 |
|
|
|
|
|
|
|
(27,694 |
) |
|
|
705,536 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
144,043 |
|
|
|
113,489 |
|
|
|
13,457 |
|
|
|
|
|
|
|
(2,224 |
) |
|
|
268,765 |
|
Selling, general and administrative expense |
|
|
16,815 |
|
|
|
15,314 |
|
|
|
9,502 |
|
|
|
26,359 |
|
|
|
|
|
|
|
67,990 |
|
Net (gain) loss on sale and disposal of assets |
|
|
(64 |
) |
|
|
3 |
|
|
|
22 |
|
|
|
72 |
|
|
|
|
|
|
|
33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
$ |
127,292 |
|
|
$ |
98,172 |
|
|
$ |
3,933 |
|
|
$ |
(26,431 |
) |
|
$ |
(2,224 |
) |
|
$ |
200,742 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
$ |
16,234 |
|
|
$ |
5,378 |
|
|
$ |
1,205 |
|
|
$ |
1,359 |
|
|
$ |
(414 |
) |
|
$ |
23,762 |
|
Capital expenditures |
|
$ |
30,473 |
|
|
$ |
8,192 |
|
|
$ |
303 |
|
|
$ |
2,198 |
|
|
$ |
(1,402 |
) |
|
$ |
39,764 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At September 30, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
1,129,515 |
|
|
$ |
206,937 |
|
|
$ |
73,394 |
|
|
$ |
200,018 |
|
|
$ |
(10,086 |
) |
|
$ |
1,599,778 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
1,069,963 |
|
|
$ |
194,164 |
|
|
$ |
42,839 |
|
|
$ |
150,891 |
|
|
$ |
(8,819 |
) |
|
$ |
1,449,038 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
12. Commitments and Contingencies
We have certain commitments, including operating leases and purchase agreements. These items
are discussed in detail in our consolidated financial statements and notes thereto included in our
2008 Annual Report on Form 10-K. We also have contingencies as follows:
a. Earn-Out Payments
We have contractual arrangements in connection with certain acquisitions that were accounted
for under previous business combinations guidance, whereby additional cash may be paid to former
owners of acquired companies upon attainment of specified financial criteria as set forth in the
respective agreements. The amount to be paid cannot be determined until the earn-out periods
expire and the attainment of criteria is established. If the specified financial criteria are
attained, at September 30, 2009, we will be obligated to pay an additional $1.3 million. We
adopted new guidance regarding business combinations for acquisitions with acquisition dates of
January 1, 2009 or later. Under the new guidance contingent consideration, such as earn-out
liabilities, is now recognized as part of the consideration transferred on the acquisition date and
a corresponding liability is recorded based on the fair value of the liability.
b. Other Contingencies
We have certain contingent liabilities resulting from litigation and claims incident to the
ordinary course of our business. We believe that the probable resolution of such contingencies
will not have a material adverse effect on our consolidated financial position, results of
operations or cash flows.
13. Recent Accounting Pronouncements
In December 2007, the FASB issued new accounting guidance related to business combinations.
The new guidance retains the underlying concepts of previous GAAP in that all business combinations
continue to be accounted for at fair value under the acquisition method of accounting. The new
guidance changes the application of the acquisition method in a number of significant respects.
Acquisition costs will generally be expensed as incurred; noncontrolling interests will be valued
at fair value at the acquisition date; restructuring costs associated with a business combination
will generally be expensed subsequent to the acquisition date; and changes in deferred tax asset
valuation allowances and income tax uncertainties after the acquisition date generally will affect
income tax expense. The new guidance is effective on a prospective basis for all of our business
combinations for which the acquisition date is on or after January 1, 2009, with the exception of
the accounting for valuation allowances on deferred taxes and acquired tax contingencies. The new
guidance amends the Codification guidance related to accounting for income taxes such that
adjustments made to valuation allowances on deferred taxes and acquired tax contingencies
associated with acquisitions that closed prior to the effective date of this guidance would also
apply its provisions.
In April 2009, the FASB issued new guidance regarding accounting for assets acquired and
liabilities assumed in a business combination that arise from contingencies. This guidance
requires recognition at fair value of such contingencies if the acquisition date fair value can be
determined during the measurement period. This guidance became effective for us for contingent
assets and liabilities arising from business combinations with acquisition dates on or after
January 1, 2009. Our adoption of this guidance did not have a material impact on our consolidated
financial statements.
In May 2009, the FASB issued new accounting guidance related to subsequent events. The new
guidance establishes general standards of accounting for and disclosure of events that occur after
the balance sheet date but before financial statements are issued or are available to be issued.
It requires disclosure of the date through which subsequent events have been evaluated and whether
that date represents the date the financial statements were issued or were available to be issued.
We adopted this guidance for the quarter ended June 30, 2009. The adoption did not have a material
impact on our consolidated financial statements.
15
VCA Antech, Inc. and Subsidiaries
Notes to Condensed, Consolidated Financial Statements (Continued)
13. Recent Accounting Pronouncements, continued
In June 2009, the FASB issued new guidance pertaining to variable interest entities. The new
guidance amends previous guidance to replace a quantitative analysis with a qualitative analysis of
interests in variable interest entities for the purpose of determining the primary beneficiary of a
variable interest entity. It also requires companies to more frequently assess whether they must
consolidate a variable interest entity. The new guidance will be effective for our company on
January 1, 2010. We are currently evaluating the impact on our consolidated financial statements;
however, we do not expect the adoption of this standard will have a material impact on our
consolidated financial statements.
In August 2009, the FASB issued Accounting Standards Update (ASU) 2009-5, Measuring
Liabilities at Fair Value. The ASU provides additional guidance in determining the fair value of
liabilities particularly in circumstances where a quoted price in an active market for an identical
liability is not readily available. It will be effective for us for the quarter ending December
31, 2009. We do not expect the adoption will have a material impact on our consolidated financial
statements.
In October 2009, the FASB issued ASU 2009-13, Multiple-Deliverable Revenue Arrangements. This
ASU amends existing GAAP for separating consideration in multiple-deliverable arrangements and
establishes a selling price hierarchy for determining the selling price of a deliverable.
Additionally, it eliminates the residual method of allocation, requires consideration be allocated
using the relative selling price method and expands required disclosures related to a vendors
multiple-deliverable revenue arrangements. This ASU is effective prospectively for revenue
arrangements entered into or materially modified in fiscal years beginning on or after June 15,
2010, with early adoption permitted. The adoption of this ASU will have a material impact on our
Medical Technology business segment. We expect that the implementation of the requirements of this
standard will result in the more timely recognition of revenue. We expect to early adopt the new
requirements no later than January 1, 2010.
In October 2009, the FASB issued ASU 2009-14, Certain Revenue Arrangements that Include
Software Elements. This ASU provides additional guidance on determining which software, if any,
relating to a tangible product should be excluded from the scope of software revenue guidance.
Additionally, it provides guidance on how to allocate consideration to deliverables in arrangements
that include both tangible products and software. It is effective prospectively for revenue
arrangements entered into or materially modified in fiscal years beginning on or after June 15,
2010, with early adoption permitted. We expect that upon adoption of this new guidance we will no
longer be governed by the previous accounting standard related to software accounting. Instead, as
mentioned above, we will now be governed by ASU 2009-13. In conjunction with the early adoption of
ASU 2009-13 as mentioned previously, we will also early adopt this ASU.
16
|
|
|
ITEM 2. |
|
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
|
|
|
|
|
|
|
Page |
|
|
|
Number |
|
|
|
|
18 |
|
|
|
|
|
|
|
|
|
18 |
|
|
|
|
|
|
|
|
|
20 |
|
|
|
|
|
|
|
|
|
21 |
|
|
|
|
|
|
|
|
|
22 |
|
|
|
|
|
|
|
|
|
27 |
|
|
|
|
|
|
|
|
|
31 |
|
17
Introduction
The following discussion should be read in conjunction with our condensed, consolidated
financial statements provided under Part I, Item I of this Quarterly report on Form 10-Q. We have
included herein statements that constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. We generally identify forward-looking statements
in this report using words like believe, intend, expect, estimate, may, plan, should
plan, project, contemplate, anticipate, predict, potential, continue, or similar
expressions. You may find some of these statements below and elsewhere in this report. These
forward-looking statements are not historical facts and are inherently uncertain and outside of our
control. Any or all of our forward-looking statements in this report may turn out to be wrong.
They can be affected by inaccurate assumptions we might make, or by known or unknown risks and
uncertainties. Many factors mentioned in our discussion in this report will be important in
determining future results. Consequently, no forward-looking statement can be guaranteed. Actual
future results may vary materially. Factors that may cause our plans, expectations, future
financial condition and results to change are described throughout this report and in our Annual
Report on Form 10-K, particularly in Risk Factors, Part I, Item 1A of that report.
The forward-looking information set forth in this Quarterly Report on Form 10-Q is as of
November 6, 2009, and we undertake no duty to update this information. Shareholders and
prospective investors can find information filed with the SEC after November 6, 2009 at our website
at http://investor.vcaantech.com or at the SECs website at www.sec.gov.
We are a leading national animal healthcare company. We provide veterinary services and
diagnostic testing to support veterinary care and we sell diagnostic imaging equipment, other
medical technology products and related services to veterinarians. Our reportable segments are as
follows:
|
|
|
Our Animal Hospital segment operates the largest network of freestanding, full-service
animal hospitals in the nation. Our animal hospitals offer a full range of general medical
and surgical services for companion animals. We treat diseases and injuries, offer
pharmaceutical and retail products and perform a variety of pet wellness programs,
including health examinations, diagnostic testing, routine vaccinations, spaying, neutering
and dental care. At September 30, 2009, our animal hospital network consisted of 482
animal hospitals in 40 states. |
|
|
|
|
Our Laboratory segment operates the largest network of veterinary diagnostic
laboratories in the nation. Our laboratories provide sophisticated testing and consulting
services used by veterinarians in the detection, diagnosis, evaluation, monitoring,
treatment and prevention of diseases and other conditions affecting animals. At September
30, 2009, our Laboratory network consisted of 46 laboratories serving all 50 states and
certain areas in Canada. |
|
|
|
|
Our Medical Technology segment sells digital radiography and ultrasound imaging
equipment, related computer hardware, software and ancillary services. |
The practice of veterinary medicine is subject to seasonal fluctuation. In particular, demand
for veterinary services is significantly higher during the warmer months because pets spend a
greater amount of time outdoors where they are more likely to be injured and are more susceptible
to disease and parasites. In addition, use of veterinary services may be affected by levels of
flea infestation, heartworm and ticks, and the number of daylight hours.
Our revenue has been adversely impacted by the current economic recession. We are unable to
forecast the timing or degree of any economic recovery. Further, trends in the general economy may
not be reflected in our business at the same time or in the same degree as in the general economy.
The timing and degree of any economic recovery, and its impact on our business, are among the
important factors that could cause our actual results to differ from our forward-looking
information.
Executive Overview
During the three months ended September 30, 2009, we generated revenue growth in spite of the
sustained weak economic environment. Although our Animal Hospital same-store revenue declined, we
achieved an increase in consolidated revenue through selective animal hospital acquisitions and our
acquisition of Eklin Medical Systems,
18
Inc. (Eklin) on July 1, 2009. Despite the challenges presented by current economic
conditions we were able to maintain our consolidated gross margin, Laboratory internal revenue and
our overall earnings.
Acquisitions and Facilities
Our growth strategy includes the acquisition of independent animal hospitals. We currently
anticipate that we will acquire $50.0 million to $60.0 million of annualized Animal Hospital
revenue in 2009. In addition, we also evaluate the acquisition of animal hospital chains,
laboratories, or related businesses if favorable opportunities are presented. The following table
summarizes the changes in the number of facilities operated by our Animal Hospital and Laboratory
segments during the nine months ended September 30, 2009:
|
|
|
|
|
Animal Hospitals: |
|
|
|
|
Beginning of period |
|
|
471 |
|
Acquisitions |
|
|
18 |
|
Acquisitions relocated into our existing animal hospitals |
|
|
(4 |
) |
Closed |
|
|
(3 |
) |
|
|
|
|
End of period |
|
|
482 |
|
|
|
|
|
|
|
|
|
|
Laboratories: |
|
|
|
|
Beginning of period |
|
|
44 |
|
Acquisitions |
|
|
2 |
|
Acquisitions relocated into our existing laboratories |
|
|
(2 |
) |
Created |
|
|
2 |
|
|
|
|
|
End of period |
|
|
46 |
|
|
|
|
|
The following table summarizes the aggregate purchase price that we paid for the 18 animal
hospitals and two laboratories we acquired during the nine months ended September 30, 2009, and the
allocation of the purchase price (in thousands):
|
|
|
|
|
Purchase Price: |
|
|
|
|
Cash (1) |
|
$ |
35,559 |
|
Non-cash note conversion to equity interest in subsidiary |
|
|
5,700 |
|
Contingent consideration |
|
|
712 |
|
|
|
|
|
Total |
|
$ |
41,971 |
|
|
|
|
|
|
|
|
|
|
Allocation of the Purchase Price: |
|
|
|
|
Tangible assets |
|
$ |
7,450 |
|
Identifiable intangible assets |
|
|
6,906 |
|
Goodwill (2) |
|
|
32,914 |
|
Other liabilities assumed |
|
|
(5,299 |
) |
|
|
|
|
Total |
|
$ |
41,971 |
|
|
|
|
|
|
|
|
(1) |
|
See the Cash Flows from Investing Activities section in the Liquidity and Capital Resources
discussion for reconciliation of cash paid for acquisitions per this schedule to the
condensed, consolidated statement of cash flows. |
|
(2) |
|
We expect that $19.3 million of the goodwill recorded for these acquisitions as of September
30, 2009 will be fully deductible for income tax purposes. |
In addition to the purchase price listed above, we made cash payments for real estate acquired
in connection with our purchase of animal hospitals totaling $3.8 million for the nine months ended
September 30, 2009.
19
Acquisition of Eklin Medical Systems, Inc.
On
July 1, 2009, we acquired Eklin, a leading seller of digital
radiography and ultrasound systems in the veterinary market. We acquired Eklin for a purchase
price of $12.5 million, net of cash acquired of $1.0 million. The following table summarizes the
purchase price and allocation of the purchase price (in thousands):
|
|
|
|
|
Purchase Price: |
|
|
|
|
Cash (1) |
|
$ |
12,483 |
|
|
|
|
|
Total |
|
$ |
12,483 |
|
|
|
|
|
|
|
|
|
|
Allocation of the Purchase Price: |
|
|
|
|
Tangible assets |
|
$ |
6,555 |
|
Identifiable intangible assets |
|
|
7,351 |
|
Goodwill (1) |
|
|
11,127 |
|
Other liabilities assumed |
|
|
(12,550 |
) |
|
|
|
|
Total |
|
$ |
12,483 |
|
|
|
|
|
|
|
|
(1) |
|
See the Cash Flows from Investing Activities section in the Liquidity and Capital Resources
discussion for reconciliation of cash paid for acquisitions per this schedule to the
condensed, consolidated statement of cash flows. |
|
(2) |
|
We expect that $2.9 million of the goodwill recorded for this acquisition as of September 30,
2009 will be fully deductible for income tax purposes. |
In addition we incurred $551,000 in transaction costs which were expensed.
Eklin has been combined with Sound Technologies, Inc. (STI) and is reported within our
Medical Technology segment.
Critical Accounting Policies
Our consolidated financial statements have been prepared in accordance with generally accepted
accounting principles in the United States (GAAP), which require management to make estimates and
assumptions that affect reported amounts. The estimates and assumptions are based on historical
experience and on other factors that management believes to be reasonable. Actual results may
differ from those estimates. Critical accounting policies represent the areas where more
significant judgments and estimates are used in the preparation of our consolidated financial
statements. A discussion of such critical accounting policies, which include revenue recognition,
valuation of goodwill and other intangible assets, income taxes, and self-insured liabilities can
be found in our 2008 Annual Report on Form 10-K. There have been no material changes to those
policies as of this Quarterly Report on Form 10-Q for the period ended September 30, 2009.
Valuation of Goodwill
In accordance with the Financial Accounting Standards Board (FASB) Accounting Standards
Codification (Codification), we are required to test our goodwill for impairment annually, or
sooner, if circumstances indicate an impairment may exist. During the quarter ended March 31,
2009, as a result of a decline in the sales volume in our Medical Technology reporting unit we
evaluated the related goodwill for impairment. We calculated an estimate of the fair value of the
Medical Technology reporting unit which indicated that there was no impairment; however, the fair
value did not significantly exceed its respective book value. Subsequent to the first quarter we
experienced an increase in sales from STI and the acquisition of Eklin, and accordingly once again
concluded that no impairment existed. However, it is reasonably possible that we could incur an
impairment to goodwill in the near term should the current economic condition worsen. We will
continue to monitor the results of all of our business segments and perform additional valuations
as necessary. We will perform our regularly scheduled annual impairment analysis of all our
reporting units as of October 31, 2009 which will include both discounted cash flow techniques and
market comparables, where applicable.
20
Consolidated Results of Operations
The following table sets forth components of our condensed, consolidated income statements
expressed as a percentage of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
2009 |
|
|
2008 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal Hospital |
|
|
76.0 |
% |
|
|
76.3 |
% |
|
|
75.8 |
% |
|
|
75.0 |
% |
Laboratory |
|
|
22.9 |
|
|
|
23.2 |
|
|
|
23.8 |
|
|
|
24.2 |
|
Medical Technology |
|
|
4.1 |
|
|
|
3.8 |
|
|
|
3.3 |
|
|
|
3.9 |
|
Intercompany |
|
|
(3.0 |
) |
|
|
(3.3 |
) |
|
|
(2.9 |
) |
|
|
(3.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
100.0 |
|
|
|
100.0 |
|
|
|
100.0 |
|
|
|
100.0 |
|
Direct costs |
|
|
73.1 |
|
|
|
73.3 |
|
|
|
72.9 |
|
|
|
72.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
26.9 |
|
|
|
26.7 |
|
|
|
27.1 |
|
|
|
27.6 |
|
Selling, general and administrative expense |
|
|
7.5 |
|
|
|
6.6 |
|
|
|
7.2 |
|
|
|
7.0 |
|
Write-off of internal-use software |
|
|
|
|
|
|
|
|
|
|
0.5 |
|
|
|
|
|
Net loss on sale and disposal of assets |
|
|
0.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
19.3 |
|
|
|
20.1 |
|
|
|
19.4 |
|
|
|
20.6 |
|
Interest expense, net |
|
|
1.4 |
|
|
|
2.1 |
|
|
|
1.6 |
|
|
|
2.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income taxes |
|
|
17.9 |
|
|
|
18.0 |
|
|
|
17.8 |
|
|
|
18.4 |
|
Provision for income taxes |
|
|
6.8 |
|
|
|
6.9 |
|
|
|
6.9 |
|
|
|
7.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
11.1 |
|
|
|
11.1 |
|
|
|
10.9 |
|
|
|
11.3 |
|
Net income attributable to noncontrolling interests |
|
|
0.4 |
|
|
|
0.3 |
|
|
|
0.3 |
|
|
|
0.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
attributable to VCA Antech, Inc. |
|
|
10.7 |
% |
|
|
10.8 |
% |
|
|
10.6 |
% |
|
|
11.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
The following table summarizes our revenue (in thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
% |
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
% |
|
|
|
$ |
|
|
Total |
|
|
$ |
|
|
Total |
|
|
Change |
|
|
$ |
|
|
Total |
|
|
$ |
|
|
Total |
|
|
Change |
|
Animal Hospital |
|
$ |
257,385 |
|
|
|
76.0 |
% |
|
$ |
253,251 |
|
|
|
76.3 |
% |
|
|
1.6 |
% |
|
$ |
757,030 |
|
|
|
75.8 |
% |
|
$ |
730,352 |
|
|
|
75.0 |
% |
|
|
3.7 |
% |
Laboratory |
|
|
77,462 |
|
|
|
22.9 |
% |
|
|
77,065 |
|
|
|
23.2 |
% |
|
|
0.5 |
% |
|
|
237,762 |
|
|
|
23.8 |
% |
|
|
235,634 |
|
|
|
24.2 |
% |
|
|
0.9 |
% |
Medical Technology |
|
|
13,732 |
|
|
|
4.1 |
% |
|
|
12,546 |
|
|
|
3.8 |
% |
|
|
9.5 |
% |
|
|
33,518 |
|
|
|
3.3 |
% |
|
|
38,233 |
|
|
|
3.9 |
% |
|
|
(12.3 |
)% |
Intercompany |
|
|
(10,017 |
) |
|
|
(3.0 |
)% |
|
|
(10,827 |
) |
|
|
(3.3 |
)% |
|
|
(7.5 |
)% |
|
|
(29,022 |
) |
|
|
(2.9 |
)% |
|
|
(29,918 |
) |
|
|
(3.1 |
)% |
|
|
(3.0 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
338,562 |
|
|
|
100.0 |
% |
|
$ |
332,035 |
|
|
|
100.0 |
% |
|
|
2.0 |
% |
|
$ |
999,288 |
|
|
|
100.0 |
% |
|
$ |
974,301 |
|
|
|
100.0 |
% |
|
|
2.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated revenue increased $6.5 million for the three months ended September 30, 2009.
The increase was primarily attributable to revenue from acquired animal hospitals and revenue from
the acquisition of Eklin. The increase was partially offset by a decline in Animal Hospital
same-store revenue of 4.9%.
Consolidated revenue increased $25.0 million for the nine months ended September 30, 2009.
The increase was primarily attributable to revenue from acquired animal hospitals and to a lesser
extent, revenue from the acquisition of Eklin and Laboratory internal revenue growth of 0.7%. The
increase was partially offset by a decline in Animal Hospital same-store revenue of 3.6% and a
decline in Medical Technology revenue excluding the results of Eklin. The nine month organic
revenue results for both the Animal Hospital and Laboratory segments have been adjusted for
differences in business days.
21
Gross Profit
The following table summarizes our gross profit in both dollars and as a percentage of
applicable revenue, or gross margin (in thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Gross |
|
|
|
|
|
|
Gross |
|
|
% |
|
|
|
|
|
|
Gross |
|
|
|
|
|
|
Gross |
|
|
% |
|
|
|
$ |
|
|
Margin |
|
|
$ |
|
|
Margin |
|
|
Change |
|
|
$ |
|
|
Margin |
|
|
$ |
|
|
Margin |
|
|
Change |
|
Animal Hospital |
|
$ |
51,213 |
|
|
|
19.9 |
% |
|
$ |
50,286 |
|
|
|
19.9 |
% |
|
|
1.8 |
% |
|
$ |
147,510 |
|
|
|
19.5 |
% |
|
$ |
144,043 |
|
|
|
19.7 |
% |
|
|
2.4 |
% |
Laboratory |
|
|
35,826 |
|
|
|
46.2 |
% |
|
|
35,273 |
|
|
|
45.8 |
% |
|
|
1.6 |
% |
|
|
112,862 |
|
|
|
47.5 |
% |
|
|
113,489 |
|
|
|
48.2 |
% |
|
|
(0.6 |
)% |
Medical Technology |
|
|
4,708 |
|
|
|
34.3 |
% |
|
|
4,322 |
|
|
|
34.4 |
% |
|
|
8.9 |
% |
|
|
12,066 |
|
|
|
36.0 |
% |
|
|
13,457 |
|
|
|
35.2 |
% |
|
|
(10.3 |
)% |
Intercompany |
|
|
(607 |
) |
|
|
|
|
|
|
(1,113 |
) |
|
|
|
|
|
|
|
|
|
|
(1,245 |
) |
|
|
|
|
|
|
(2,224 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total gross profit |
|
$ |
91,140 |
|
|
|
26.9 |
% |
|
$ |
88,768 |
|
|
|
26.7 |
% |
|
|
2.7 |
% |
|
$ |
271,193 |
|
|
|
27.1 |
% |
|
$ |
268,765 |
|
|
|
27.6 |
% |
|
|
0.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated gross profit increased $2.4 million for the three months ended September 30,
2009. The increase was primarily due to acquired animal hospitals and the acquisition of Eklin as
discussed above.
Consolidated gross profit increased $2.4 million for the nine months ended September 30, 2009.
The increase was primarily due to acquired animal hospitals, the acquisition of Eklin and
Laboratory internal growth. The increase was largely offset by a decline in Medical Technology
revenue excluding the results of Eklin and modest declines in Animal Hospital and Laboratory gross
margins.
Segment Results
Animal Hospital Segment
The following table summarizes revenue, gross profit and gross margin for our Animal Hospital
segment (in thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2009 |
|
2008 |
|
% Change |
|
2009 |
|
2008 |
|
% Change |
Revenue |
|
$ |
257,385 |
|
|
$ |
253,251 |
|
|
|
1.6 |
% |
|
$ |
757,030 |
|
|
$ |
730,352 |
|
|
|
3.7 |
% |
Gross profit |
|
$ |
51,213 |
|
|
$ |
50,286 |
|
|
|
1.8 |
% |
|
$ |
147,510 |
|
|
$ |
144,043 |
|
|
|
2.4 |
% |
Gross margin |
|
|
19.9 |
% |
|
|
19.9 |
% |
|
|
|
|
|
|
19.5 |
% |
|
|
19.7 |
% |
|
|
|
|
Animal Hospital revenue increased $4.1 million for the three months ended September 30, 2009
and $26.7 million for the nine months ended September 30, 2009 as compared to the same periods in
the prior year. The components of the increase are summarized in the following table (in
thousands, except percentages and average price per order):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
% Change |
|
|
2009 |
|
|
2008 |
|
|
% Change |
|
Same-store facilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Orders (1) (2) |
|
|
1,596 |
|
|
|
1,714 |
|
|
|
(6.9 |
)% |
|
|
4,334 |
|
|
|
4,624 |
|
|
|
(6.3 |
)% |
Average revenue per order (3) |
|
$ |
149.79 |
|
|
$ |
146.63 |
|
|
|
2.2 |
% |
|
$ |
151.40 |
|
|
$ |
147.25 |
|
|
|
2.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Same-store revenue (1) |
|
$ |
239,041 |
|
|
$ |
251,274 |
|
|
|
(4.9 |
)% |
|
$ |
656,243 |
|
|
$ |
680,895 |
|
|
|
(3.6 |
)% |
Business day adjustment (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,832 |
|
|
|
|
|
Net acquired revenue (5) |
|
|
18,344 |
|
|
|
1,977 |
|
|
|
|
|
|
|
100,787 |
|
|
|
46,625 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
257,385 |
|
|
$ |
253,251 |
|
|
|
1.6 |
% |
|
$ |
757,030 |
|
|
$ |
730,352 |
|
|
|
3.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Same-store revenue and orders were calculated using Animal Hospital operating results,
adjusted to exclude the operating results for newly acquired animal hospitals that we did not
own as of the beginning of the comparable |
22
|
|
|
|
|
period in the prior period, and adjusted for the
impact resulting from any differences in the number of business days in the comparable period.
Same-store revenue also includes revenue generated by customers referred from our relocated
or combined animal hospitals, including those merged upon acquisition. |
|
(2) |
|
The change in orders may not calculate exactly due to rounding. |
|
(3) |
|
Computed by dividing same-store revenue by same-store orders. The average revenue per order
may not calculate exactly due to rounding. |
|
(4) |
|
The business day adjustment reflects the impact of one fewer business day in the nine months
ended September 30, 2009 as compared to the nine months ended September 30, 2008. |
|
(5) |
|
Net acquired revenue represents the revenue from those animal hospitals acquired, net of
revenue from those animal hospitals sold or closed, on or after the beginning of the
comparable period, which was July 1, 2008 for the three month analysis and January 1, 2008 for
the nine month analysis. Fluctuations in net acquired revenue occur due to the volume, size,
and timing of acquisitions and dispositions during the periods from this date through the end
of the applicable period. |
Over the last few years, some pet-related products traditionally sold in our animal hospitals
are now widely available in retail stores and other distribution channels such as the Internet.
There has also been a decline in the number of vaccinations as some recent professional literature
and research has suggested that vaccinations can be given to pets less frequently.
Our business strategy is to place a greater emphasis on comprehensive wellness visits and
advanced medical procedures, which typically generate higher priced orders. The migration of lower
priced orders from our animal hospitals to other distribution channels mentioned above and our
emphasis on comprehensive wellness visits has resulted in a decrease in lower priced orders and an
increase in higher priced orders. However, during the three and nine months ended September 30,
2009 we experienced a decrease in both lower and higher priced orders primarily as a result of
current economic conditions and to a lesser extent the impact of changes in our overall business
environment on the mix of tests performed.
Price increases also contributed to the increase in the average revenue per order. Prices at
each of our animal hospitals are reviewed regularly and adjustments are made based on market
considerations, demographics and our costs. These adjustments historically have approximated 3% to
6% on many services at the majority of our animal hospitals and are typically implemented in
February of each year.
Animal Hospital gross profit is calculated as Animal Hospital revenue less Animal Hospital
direct costs. Animal Hospital direct costs are comprised of all costs of services and products at
the animal hospitals, including, but not limited to, salaries of veterinarians, technicians and all
other animal hospital-based personnel, facilities rent, occupancy costs, supply costs, depreciation
and amortization, certain marketing and promotional expenses incurred by each individual animal
hospital, and costs of goods sold associated with the retail sales of pet food and pet supplies.
Our combined Animal Hospital gross margin remained unchanged at 19.9% for both the three
months ended September 30, 2009 and 2008. Our same-store gross margin increased slightly to 20.5%
for the three months ended September 30, 2009 as compared to 20.1% in the prior year period. The
increase in same-store gross margin was fully offset by lower gross margins from our acquired
animal hospitals.
Our combined Animal Hospital gross margin decreased slightly to 19.5% for the nine months
ended September 30, 2009 as compared to 19.7% in the prior year period. The decrease was due to
lower gross margins from our acquired animal hospitals. The decrease was largely offset by an
increase in same-store gross margin to 20.4% for the nine months ended September 30, 2009 as
compared to 20.3% in the prior year period.
The increase in same-store gross margin for the three and nine months ended September 30, 2009
was due to a decrease in labor costs related to our efforts to manage our margin as well as a
decrease in workers compensation and health insurance expense. These improvements were largely
offset by increases in pet food expense, medical supplies expense and depreciation and
amortization.
Over the last several years we have acquired a significant number of animal hospitals. Many
of these newly acquired animal hospitals had lower gross margins at the time of acquisition than
those previously operated by us.
We have improved these lower gross margins, in the aggregate, subsequent to the acquisition by
improving animal hospital revenue, reducing costs and/or increasing operating leverage.
23
Laboratory Segment
The following table summarizes revenue and gross profit for our Laboratory segment (in
thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2009 |
|
2008 |
|
%
Change |
|
2009 |
|
2008 |
|
%
Change |
Revenue |
|
$ |
77,462 |
|
|
$ |
77,065 |
|
|
|
0.5 |
% |
|
$ |
237,762 |
|
|
$ |
235,634 |
|
|
|
0.9 |
% |
Gross profit |
|
$ |
35,826 |
|
|
$ |
35,273 |
|
|
|
1.6 |
% |
|
$ |
112,862 |
|
|
$ |
113,489 |
|
|
|
(0.6 |
)% |
Gross margin |
|
|
46.2 |
% |
|
|
45.8 |
% |
|
|
|
|
|
|
47.5 |
% |
|
|
48.2 |
% |
|
|
|
|
Laboratory revenue increased $397,000 for the three months ended September 30, 2009 and $2.1
million for the nine months ended September 30, 2009 as compared to the same periods in the prior
year. The components of the increase in Laboratory revenue are detailed below (in thousands,
except percentages and average price per requisition):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
%
Change |
|
|
2009 |
|
|
2008 |
|
|
%
Change |
|
Internal growth: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of requisitions (1) |
|
|
3,288 |
|
|
|
3,306 |
|
|
|
(0.5 |
)% |
|
|
10,138 |
|
|
|
10,102 |
|
|
|
0.4 |
% |
Average revenue per requisition (2) |
|
$ |
23.41 |
|
|
$ |
23.31 |
|
|
|
0.4 |
% |
|
$ |
23.31 |
|
|
$ |
23.23 |
|
|
|
0.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total internal revenue (1) |
|
$ |
76,986 |
|
|
$ |
77,065 |
|
|
|
(0.1 |
)% |
|
$ |
236,356 |
|
|
$ |
234,637 |
|
|
|
0.7 |
% |
Billing day adjustment (3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
997 |
|
|
|
|
|
Acquired revenue (4) |
|
|
476 |
|
|
|
|
|
|
|
|
|
|
|
1,406 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
77,462 |
|
|
$ |
77,065 |
|
|
|
0.5 |
% |
|
$ |
237,762 |
|
|
$ |
235,634 |
|
|
|
0.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Internal revenue and requisitions were calculated using Laboratory operating results,
adjusted to exclude the operating results of acquired laboratories for the comparable periods
that we did not own them in the prior year and adjusted for the impact resulting from any
differences in the number of billing days in comparable periods. |
|
(2) |
|
Computed by dividing internal revenue by the number of requisitions. |
|
(3) |
|
The billing day adjustment reflects the impact of one fewer billing day in the nine months
ended September 30, 2009 as compared to the nine months ended September 30, 2008. |
|
(4) |
|
Acquired revenue represents the revenue recognized from our acquired laboratories for the
comparable current year period that we did not own them in the prior year. |
The increase in Laboratory revenue for the three months ended September 30, 2009 was due to
acquired revenue, partially offset by a slight decline in internal revenue. The increase in
Laboratory revenue for the nine months ended September 30, 2009 was due to acquired revenue and an
increase in internal revenue, partially offset by the impact of one fewer business day as compared
to the prior year period.
Requisitions from internal growth have been driven by an ongoing trend in veterinary medicine
to focus on the importance of laboratory diagnostic testing in the diagnosis, early detection and
treatment of diseases, and the migration of certain tests to outside laboratories that have
historically been performed in animal hospitals. While these factors have resulted in significant
increases in internal requisitions in the past, due to the economic downturn requisitions from
internal growth have remained relatively flat for the three and nine months ended September 30,
2009.
The average revenue per requisition increased slightly for the three and nine months ended
September 30, 2009 as compared to prior year periods due to price increases which ranged from 3% to
4% in both February 2009 and February 2008. The price increases were largely offset by other
factors including changes in the mix, performing lower-priced tests historically performed at the
animal hospitals, and a decrease in higher-priced tests as a result of the current economic
environment.
24
Laboratory gross profit is calculated as Laboratory revenue less Laboratory direct costs.
Laboratory direct costs are comprised of all costs of laboratory services, including but not
limited to, salaries of veterinarians, specialists, technicians and other laboratory-based
personnel, transportation and delivery costs, facilities rent, occupancy costs, depreciation and
amortization and supply costs.
Our Laboratory gross margin increased slightly to 46.2% for the three months ended September
30, 2009 as compared to 45.8% in the prior year period. The increase was due to decreased salaries
expense, workers compensation and freight expense, offset by increased depreciation and
amortization expense related to new equipment purchases and leasehold improvements. Our Laboratory
gross margin decreased slightly to 47.5% for the nine months ended September 30, 2009 as compared
to 48.2% in the prior year period. The decrease was primarily due to costs incurred in advance of
projected revenue related to our expansion into Canada, in addition to the increased depreciation
and amortization expense mentioned above. Excluding the results for Canada our Laboratory margins
would have increased 60 basis points for the three months ended September 30, 2009, and would have
decreased only 12 basis points for the nine months ended September 30, 2009.
Medical Technology Segment
The following table summarizes revenue and gross profit for our Medical Technology segment (in
thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2009 |
|
2008 |
|
% Change |
|
2009 |
|
2008 |
|
% Change |
Revenue |
|
$ |
13,732 |
|
|
$ |
12,546 |
|
|
|
9.5 |
% |
|
$ |
33,518 |
|
|
$ |
38,233 |
|
|
|
(12.3 |
)% |
Gross profit |
|
$ |
4,708 |
|
|
$ |
4,322 |
|
|
|
8.9 |
% |
|
$ |
12,066 |
|
|
$ |
13,457 |
|
|
|
(10.3 |
)% |
Gross margin |
|
|
34.3 |
% |
|
|
34.4 |
% |
|
|
|
|
|
|
36.0 |
% |
|
|
35.2 |
% |
|
|
|
|
Medical Technology revenue increased $1.2 million for the three months ended September 30,
2009 as compared to the prior year period due to the acquisition of Eklin. Excluding Eklin
results, Medical Technology revenue decreased for the three months ended September 30, 2009 as
compared to the prior year period. The decrease was primarily due to a decrease in the sale of
digital radiography equipment as a result of current economic trends, which have caused many
members of the veterinary community to delay their expenditures for capital assets.
Medical Technology revenue decreased $4.7 million for the nine months ended September 30, 2009
as compared to the prior year period. The decrease was primarily due to a decrease in the sale of
digital radiography and ultrasound equipment as a result of the economic conditions mentioned
above. Additionally, the sale of ultrasound equipment has decreased due to the maturing of the
market for this type of equipment. The overall decline in revenue was partially offset by an
increase in customer support revenue related to an increase in the base of installed digital
radiography units and an overall increase in renewal rates.
Medical Technology gross profit is calculated as Medical Technology revenue less Medical
Technology direct costs. Medical Technology direct costs are comprised of all product and service
costs, including, but not limited to, all costs of equipment, related products and services,
salaries of technicians, support personnel, trainers, consultants and other non-administrative
personnel, depreciation and amortization and supply costs.
Medical Technology gross profit increased $386,000 for the three months ended September 30,
2009 and decreased $1.4 million for the nine months ended September 30, 2009, as compared to prior
year periods. Excluding Eklin results, Medical Technology gross profit decreased for the three and
nine months ended September 30, 2009 as compared to prior year periods. The decrease is
attributable to the decrease in revenue as discussed above and a decline in digital radiography and
ultrasound margins. The decline in digital radiography margins was the result of a change in
product mix from higher-margin small-animal business to lower-margin equine business. The decline
in ultrasound margins was due to an increase in the sale of premium ultrasound products which
typically yield lower margins.
25
Intercompany Revenue
Laboratory revenue for the three and nine months ended September 30, 2009 included
intercompany revenue of $8.0 million and $24.4 million, respectively, that was generated by
providing laboratory services to our animal hospitals. Medical Technology revenue for the three
and nine months ended September 30, 2009 included intercompany revenue of $2.1 million and $4.6
million, respectively, that was generated by providing products and services to our animal
hospitals and laboratories. For purposes of reviewing the operating performance of our business
segments, all intercompany transactions are accounted for as if the transaction was with an
independent third party at current market prices. For financial reporting purposes, intercompany
transactions are eliminated as part of our consolidation.
Selling, General and Administrative Expense
The following table summarizes our selling, general and administrative expense (SG&A) in
both dollars and as a percentage of applicable revenue (in thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
% |
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
% |
|
|
|
$ |
|
|
Revenue |
|
|
$ |
|
|
Revenue |
|
|
Change |
|
|
$ |
|
|
Revenue |
|
|
$ |
|
|
Revenue |
|
|
Change |
|
Animal Hospital |
|
$ |
5,162 |
|
|
|
2.0 |
% |
|
$ |
5,643 |
|
|
|
2.2 |
% |
|
|
(8.5 |
)% |
|
$ |
15,924 |
|
|
|
2.1 |
% |
|
$ |
16,815 |
|
|
|
2.3 |
% |
|
|
(5.3 |
)% |
Laboratory |
|
|
5,621 |
|
|
|
7.3 |
% |
|
|
5,178 |
|
|
|
6.7 |
% |
|
|
8.6 |
% |
|
|
16,832 |
|
|
|
7.1 |
% |
|
|
15,314 |
|
|
|
6.5 |
% |
|
|
9.9 |
% |
Medical Technology |
|
|
4,316 |
|
|
|
31.4 |
% |
|
|
3,120 |
|
|
|
24.9 |
% |
|
|
38.3 |
% |
|
|
10,058 |
|
|
|
30.0 |
% |
|
|
9,502 |
|
|
|
24.9 |
% |
|
|
5.9 |
% |
Corporate |
|
|
10,159 |
|
|
|
3.0 |
% |
|
|
8,062 |
|
|
|
2.4 |
% |
|
|
26.0 |
% |
|
|
28,838 |
|
|
|
2.9 |
% |
|
|
26,359 |
|
|
|
2.7 |
% |
|
|
9.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total SG&A |
|
$ |
25,258 |
|
|
|
7.5 |
% |
|
$ |
22,003 |
|
|
|
6.6 |
% |
|
|
14.8 |
% |
|
$ |
71,652 |
|
|
|
7.2 |
% |
|
$ |
67,990 |
|
|
|
7.0 |
% |
|
|
5.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated SG&A increased $3.3 million for the three months ended September 30, 2009 and
$3.7 million for the nine months ended September 30, 2009. Laboratory SG&A increased primarily due
to costs incurred related to our expansion into Canada, research and development expense associated
with potential new products and an increase in marketing expense. Medical Technology SG&A
increased due to the acquisition of Eklin and increases in salaries, commission and consulting
expenses. Corporate SG&A increased due to an increase in payroll-related expenses and transaction
costs incurred related to our acquisition of Eklin. Effective January 1, 2009, transaction costs
are now expensed in accordance with the new business combinations guidance. The increases in
Laboratory, corporate and Medical Technology SG&A were partially offset by a decrease in Animal
Hospital SG&A. This decrease was due to reductions in travel and entertainment expense and
decreased bonuses and commissions as a result of the current economic environment.
Operating Income
The following table summarizes our operating income in both dollars and as a percentage of
applicable revenue (in thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
% |
|
|
|
|
|
|
% of |
|
|
|
|
|
|
% of |
|
|
% |
|
|
|
$ |
|
|
Revenue |
|
|
$ |
|
|
Revenue |
|
|
Change |
|
|
$ |
|
|
Revenue |
|
|
$ |
|
|
Revenue |
|
|
Change |
|
Animal Hospital |
|
$ |
45,651 |
|
|
|
17.7 |
% |
|
$ |
44,618 |
|
|
|
17.6 |
% |
|
|
2.3 |
% |
|
$ |
131,316 |
|
|
|
17.3 |
% |
|
$ |
127,292 |
|
|
|
17.4 |
% |
|
|
3.2 |
% |
Laboratory |
|
|
30,204 |
|
|
|
39.0 |
% |
|
|
30,092 |
|
|
|
39.0 |
% |
|
|
0.4 |
% |
|
|
96,002 |
|
|
|
40.4 |
% |
|
|
98,172 |
|
|
|
41.7 |
% |
|
|
(2.2 |
)% |
Medical Technology |
|
|
391 |
|
|
|
2.8 |
% |
|
|
1,200 |
|
|
|
9.6 |
% |
|
|
(67.4 |
)% |
|
|
2,001 |
|
|
|
6.0 |
% |
|
|
3,933 |
|
|
|
10.3 |
% |
|
|
(49.1 |
)% |
Corporate |
|
|
(10,166 |
) |
|
|
(3.0 |
)% |
|
|
(8,122 |
) |
|
|
(2.4 |
)% |
|
|
25.2 |
% |
|
|
(34,137 |
) |
|
|
(3.4 |
)% |
|
|
(26,431 |
) |
|
|
(2.7 |
)% |
|
|
29.2 |
% |
Intercompany |
|
|
(607 |
) |
|
|
6.1 |
% |
|
|
(1,113 |
) |
|
|
10.3 |
% |
|
|
(45.5 |
)% |
|
|
(1,245 |
) |
|
|
4.3 |
% |
|
|
(2,224 |
) |
|
|
7.4 |
% |
|
|
(44.0 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating income |
|
$ |
65,473 |
|
|
|
19.3 |
% |
|
$ |
66,675 |
|
|
|
20.1 |
% |
|
|
(1.8 |
)% |
|
$ |
193,937 |
|
|
|
19.4 |
% |
|
$ |
200,742 |
|
|
|
20.6 |
% |
|
|
(3.4 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The decrease in our consolidated operating income during the three months ended September 30,
2009 was primarily due to an increase in SG&A expense as a percentage of revenue.
26
The decrease in our consolidated operating income during the nine months ended September 30,
2009 was primarily due to a $5.3 million non-cash charge taken during the three months ended June
30, 2009 related to the write-off of an internal-use software project due to the failure of the
project to reach development milestones and our decision to pursue alternative solutions. The
decrease was also due to an increase in SG&A expense as a percentage of revenue.
Interest Expense, Net
The following table summarizes our interest expense, net of interest income (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
|
2009 |
|
|
2008 |
|
Interest expense (income): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior term notes |
|
$ |
2,406 |
|
|
$ |
5,385 |
|
|
$ |
7,566 |
|
|
$ |
17,961 |
|
Interest rate hedging agreements |
|
|
1,895 |
|
|
|
1,639 |
|
|
|
7,867 |
|
|
|
4,077 |
|
Capital leases and other |
|
|
567 |
|
|
|
395 |
|
|
|
1,716 |
|
|
|
1,437 |
|
Amortization of debt costs |
|
|
122 |
|
|
|
118 |
|
|
|
363 |
|
|
|
351 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,990 |
|
|
|
7,537 |
|
|
|
17,512 |
|
|
|
23,826 |
|
Interest income |
|
|
(182 |
) |
|
|
(828 |
) |
|
|
(860 |
) |
|
|
(2,457 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total interest expense, net of interest income |
|
$ |
4,808 |
|
|
$ |
6,709 |
|
|
$ |
16,652 |
|
|
$ |
21,369 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The decrease in net interest expense for the three and nine months ended September 30, 2009
was primarily attributable to a decrease in the weighted-average interest rate in comparison to the
prior year. The decrease was partially offset by an increase in interest expense related to our
fixed-rate swap agreements due to a decrease in London Interbank Offer Rates (LIBOR) in
comparison to the prior year.
Provision for Income Taxes
Our effective tax rate was 38.9% and 39.1% for the three and nine months ended September 30,
2009, respectively, compared to 39.1% for both the three and nine months ended September 30, 2008.
The effective tax rate is subject to ongoing review and evaluation by management and could change
in future quarters.
Liquidity and Capital Resources
Introduction
We generate cash primarily from payments made by customers for our veterinary services,
payments from animal hospitals and other clients for our laboratory services, and from proceeds
received from the sale of our imaging equipment and other related services. Our business
historically has experienced strong liquidity, as fees for services provided in our animal
hospitals are due at the time of service and fees for laboratory services are collected under
standard industry terms. Our cash disbursements are primarily for payments related to the
compensation of our employees, supplies and inventory purchases for our operating segments,
occupancy and other administrative costs, interest expense, payments on long-term borrowings,
capital expenditures and animal hospital acquisitions. Cash outflows fluctuate with the amount and
timing of the settlement of these transactions.
We manage our cash, investments and capital structure so we are able to meet the short-term
and long-term obligations of our business while maintaining financial flexibility and liquidity.
We forecast, analyze and monitor our cash flows to enable investment and financing within the
overall constraints of our financial strategy.
At September 30, 2009, our consolidated cash and cash equivalents totaled $155.0 million,
representing an increase of $66.0 million as compared to December 31, 2008. In addition, cash
flows generated from operating activities totaled $156.3 million in the nine months ended September
30, 2009, representing an increase of $10.8 million as compared to the nine months ended September
30, 2008.
We have historically funded our working capital requirements, capital expenditures and
investment in individual animal hospital acquisitions from internally generated cash flows and we
expect to do so in the future. As of September 30, 2009, we have access to an unused $75.0 million
revolving credit facility, which allows us to
27
maintain further operating and financial flexibility.
Historically, we have been able to obtain cash from other additional borrowings. The availability
of financing in the form of debt or equity is influenced by many factors including our
profitability, operating cash flows, debt levels, debt ratings, contractual restrictions and market
conditions. Although in the past we have been able to obtain financing for material transactions
on terms that we believe to be reasonable, there is a possibility that we may not be able to obtain
financing on favorable terms in the future.
Future Cash Flows
Short-Term
Other than our acquisitions of animal hospital chains, we historically have funded our working
capital requirements, capital expenditures and investments in animal hospital acquisitions from
internally generated cash flow. We anticipate that our cash on hand and net cash provided by
operations will be sufficient to meet our anticipated cash requirements for the next 12 months. If
we consummate one or more significant acquisitions of animal hospital chains during this period, we
may seek additional debt or equity financing.
For the year ended December 31, 2009, we expect to spend $50.0 million to $60.0 million,
excluding real estate, related to the acquisition of independent animal hospitals. The ultimate
number of acquisitions and cash used is largely dependent upon the attractiveness of the candidates
and the strategic fit within our operations. From January 1, 2009 through September 30, 2009, we
spent $35.6 million in connection with the acquisition of 17 animal hospitals and two laboratories,
as well as $3.8 million for the related real estate. On July 1, 2009 we spent approximately $12.5
million in connection with the acquisition of Eklin. In addition, we expect to spend approximately
$60.0 million in 2009 for both property and equipment additions and capital costs necessary to
maintain our existing facilities.
Long-Term
Our long-term liquidity needs, other than those related to the day-to-day operations of our
business, including commitments for operating leases, generally are comprised of scheduled
principal and interest payments for our outstanding long-term indebtedness, capital expenditures
related to the expansion of our business, and acquisitions in accordance with our growth strategy.
In addition to the scheduled payments on our senior-term notes, we are required to make mandatory
prepayments in the event we have excess cash flow. Pursuant to the terms of our senior credit
facility, mandatory prepayments are due on our senior-term notes equal to 75% of any excess cash
flow at the end of 2009 and 2010. Excess cash flow is defined as earnings before interest, taxes,
depreciation and amortization, less voluntary and scheduled debt repayments, capital expenditures,
interest payable in cash, taxes payable in cash and cash paid for acquisitions. These payments
reduce on a pro rata basis the remaining scheduled principal payments.
We expect that our long-term cash flow from operations will not be sufficient to repay our
long-term debt when it comes due in May 2011. We anticipate that we will refinance such
indebtedness, amend its terms to extend the maturity dates, or issue common stock in our company.
Our management cannot make any assurances that such refinancing, amendments, or equity offering, if
necessary, will be available on attractive terms, if at all.
Debt Related Covenants
Our senior credit facility contains certain financial covenants pertaining to fixed-charge
coverage and leverage ratios. In addition, the senior credit facility has restrictions pertaining
to capital expenditures, acquisitions and the payment of cash dividends. As of September 30, 2009,
we were in compliance with these covenants.
At September 30, 2009, we had a fixed-charge coverage ratio of 1.69 to 1.00, which was in
compliance with the required ratio of no less than 1.20 to 1.00. The senior credit facility
defines the fixed-charge coverage ratio as that ratio that is calculated on a last 12-month basis
by dividing pro forma earnings before interest, taxes, depreciation and amortization, as defined by
the senior credit facility (pro forma earnings), by fixed charges. Fixed charges are defined as
cash interest expense, scheduled principal payments on debt obligations, capital expenditures, and
provision for income taxes. Pro forma earnings include 12 months of operating results for
businesses acquired during the period.
28
At September 30, 2009, we had a leverage ratio of 1.85 to 1.00, which was in compliance with
the required ratio of no more than 2.75 to 1.00. The senior credit facility defines the leverage
ratio as that ratio which is calculated as total debt divided by pro forma earnings.
Historical Cash Flows
The following table summarizes our cash flows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
|
2009 |
|
|
2008 |
|
Cash provided by (used in): |
|
|
|
|
|
|
|
|
Operating activities |
|
$ |
156,321 |
|
|
$ |
145,562 |
|
Investing activities |
|
|
(94,520 |
) |
|
|
(157,852 |
) |
Financing activities |
|
|
4,224 |
|
|
|
(3,229 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
|
17 |
|
|
|
(44 |
) |
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents |
|
|
66,042 |
|
|
|
(15,563 |
) |
Cash and cash equivalents at beginning of period |
|
|
88,959 |
|
|
|
110,866 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
155,001 |
|
|
$ |
95,303 |
|
|
|
|
|
|
|
|
Cash Flows from Operating Activities
Net cash provided by operating activities increased $10.8 million in the nine months ended
September 30, 2009 as compared to the prior year period. This increase was primarily due to
additional cash generated from acquired businesses and decreases in cash paid for interest and cash
paid for taxes. The increase was partially offset by a larger decrease in working capital as
compared to the prior year period.
Cash Flows from Investing Activities
The table below presents the components of the changes in investing cash flows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
|
September 30, |
|
|
|
|
|
|
2009 |
|
|
2008 |
|
|
Variance |
|
Investing Cash Flows: |
|
|
|
|
|
|
|
|
|
Acquisition of independent animal
hospitals and laboratories |
|
$ |
(35,559 |
) |
|
$ |
(88,136 |
) |
|
$ |
52,577 |
(1) |
Acquisition of Eklin |
|
|
(12,483 |
) |
|
|
|
|
|
|
(12,483 |
) (2) |
Other |
|
|
(3,811 |
) |
|
|
(1,639 |
) |
|
|
(2,172 |
) |
|
|
|
|
|
|
|
|
|
|
Total cash used for acquisitions |
|
|
(51,853 |
) |
|
|
(89,775 |
) |
|
|
37,922 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment additions |
|
|
(38,522 |
) |
|
|
(39,764 |
) |
|
|
1,242 |
|
Real estate acquired with acquisitions |
|
|
(3,828 |
) |
|
|
(15,063 |
) |
|
|
11,235 |
(3) |
Proceeds from sale of assets |
|
|
123 |
|
|
|
1,774 |
|
|
|
(1,651 |
) (4) |
Other |
|
|
(440 |
) |
|
|
(15,024 |
) |
|
|
14,584 |
(5) |
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
$ |
(94,520 |
) |
|
$ |
(157,852 |
) |
|
$ |
63,332 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The number of acquisitions will vary from year to year based upon the available pool of
suitable candidates. In addition, the cash used for acquisitions declined in 2009 as a
result of our desire to accumulate cash in advance of our debt refinancing which is expected
to occur early next year. |
|
(2) |
|
As mentioned previously, on July 1, 2009 we acquired Eklin. See further discussion of the
acquisition in the Executive Overview above. |
29
|
|
|
(3) |
|
Due to the lower return on investment realized on acquired real estate we are highly
selective in our decision to acquire real estate. The decrease in cash used to acquire real
estate is due to a decrease in opportunities that met our selective criteria. |
|
(4) |
|
The decrease in proceeds from sale of assets is primarily due to a significant land sale in
2008. |
|
(5) |
|
The decrease in other investing cash flows was primarily due to investments made in 2008
related to our expansion into other markets. |
Cash Flows from Financing Activities
The table below presents the components of the changes in financing cash flows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
|
September 30, |
|
|
|
|
|
|
2009 |
|
|
2008 |
|
|
Variance |
|
Financing Cash Flows: |
|
|
|
|
|
|
|
|
|
Repayment of long-term obligations |
|
$ |
(5,898 |
) |
|
$ |
(5,852 |
) |
|
$ |
(46 |
) |
Distributions to noncontrolling interest partners |
|
|
(3,018 |
) |
|
|
(2,797 |
) |
|
|
(221 |
) (1) |
Proceeds from stock options exercises |
|
|
13,110 |
|
|
|
3,574 |
|
|
|
9,536 |
(2) |
Excess tax benefits from stock options |
|
|
591 |
|
|
|
1,846 |
|
|
|
(1,255 |
) |
Stock repurchases |
|
|
(561 |
) |
|
|
|
|
|
|
(561 |
) (3) |
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities |
|
$ |
4,224 |
|
|
$ |
(3,229 |
) |
|
$ |
7,453 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The distributions to noncontrolling interest partners represent cash payments to
noncontrolling interest partners for their portion of the partnerships excess cash. As
mentioned in Note 4 in our September 30, 2009 Notes to Condensed, Consolidated Financial
Statements, we adopted new noncontrolling interest guidance effective January 1, 2009, which
resulted in a reclassification of these distributions from operating activities to financing
activities. |
|
(2) |
|
The number of stock option exercises has increased in comparison to the prior year related to
the increase in the market price of our stock during the nine months ended September 30, 2009
and the nearing expiration of certain stock options. |
|
(3) |
|
The stock repurchases in fiscal 2009 represent cash paid for income taxes on behalf of
employees who elected to settle their tax obligations on vested stocks with a portion of the
stocks that vested. |
Off-Balance Sheet Arrangements
Other than operating leases, as of September 30, 2009 we do not have any off-balance sheet
financing arrangements.
Interest Rate Swap Agreements
We have interest rate swap agreements whereby we pay counterparties amounts based on fixed
interest rates and set notional principal amounts in exchange for the receipt of payments from the
counterparties based on LIBOR and the same set notional principal amounts. We entered into these
interest rate swap agreements to hedge against the risk of increasing interest rates. The
contracts effectively convert a certain amount of our variable-rate debt under our senior credit
facility to fixed-rate debt for purposes of controlling cash paid for interest. That amount is
equal to the notional principal amount of the interest rate swap agreements, and the fixed-rate
conversion period is equal to the terms of the contract. All of our interest rate swap agreements
qualify for hedge accounting and are summarized as follows:
30
|
|
|
|
|
|
|
|
|
|
|
Interest Rate Swap Agreements |
Fixed interest rate
|
|
|
5.34% |
|
|
|
2.64% |
|
Notional amount (in millions)
|
|
|
$100.0 |
|
|
|
$100.0 |
|
Effective date
|
|
|
6/11/2007 |
|
|
|
2/12/2008 |
|
Expiration date
|
|
|
12/31/2009 |
|
|
|
2/26/2010 |
|
Counterparty
|
|
Goldman Sachs
|
|
Wells Fargo
|
Qualifies for hedge accounting
|
|
Yes
|
|
Yes
|
In the future, we may enter into additional interest rate strategies. However, we have not
yet determined what those strategies will be or their possible impact.
Description of Indebtedness
Senior Credit Facility
At September 30, 2009, we had $518.2 million principal amount outstanding under our
senior-term notes and no borrowings outstanding under our revolving credit facility.
We pay interest on our senior-term notes based on the interest rate offered to our
administrative agent on LIBOR plus a margin of 1.50% per annum. We pay interest on our revolving
credit facility based upon Wells Fargos prime rate plus the margin of 0.50%.
The senior-term notes mature in May 2011 and the revolving credit facility matures in May
2010.
Other Debt and Capital Lease Obligations
At September 30, 2009, we had seller notes secured by assets of certain animal hospitals,
unsecured debt and capital leases that totaled $28.8 million.
Recent Accounting Pronouncements
In June 2009, the FASB issued the FASB Accounting Standards Codification (Codification) as
the single source of GAAP. The Codification was effective for our company beginning July 1, 2009.
The Codification does not change GAAP and did not impact our consolidated financial statements.
On January 1, 2008, we adopted the applicable provisions of the new accounting guidance on
fair value measurements which defines fair value, establishes a framework for measuring fair value
and expands disclosures about fair value measurements related to financial instruments. On January
1, 2009 we adopted the new guidance for our non-financial assets and non-financial liabilities
measured on a non-recurring basis. As of September 30, 2009, we do not have any applicable
non-recurring measurements of non-financial assets and non-financial liabilities.
Effective January 1, 2009, we adopted the new accounting guidance on noncontrolling interests
on a retrospective basis. The new guidance changes the accounting and reporting for minority
interests which have been re-characterized as noncontrolling interests and are now classified as a
component of equity in our condensed, consolidated balance sheets. The adoption also resulted in
new presentation and disclosure requirements for noncontrolling interests within our condensed,
consolidated income statements, statements of equity and statements of cash flows. The adoption
did not have a material impact on our consolidated financial statements.
In December 2007, the FASB issued new accounting guidance related to business combinations.
The new guidance retains the underlying concepts of previous GAAP in that all business combinations
continue to be accounted for at fair value under the acquisition method of accounting. The new guidance
changes the application of the acquisition method in a number of significant respects. Acquisition
costs will generally be expensed as incurred; noncontrolling interests will be valued at fair value
at the acquisition date; restructuring costs associated with a business combination will generally
be expensed subsequent to the acquisition date; and changes in deferred tax asset valuation
allowances and income tax uncertainties after the acquisition date generally will affect income tax
expense. The new guidance is effective on a prospective basis for all of our business combinations
for which the acquisition date is on or after January 1, 2009, with the exception of the accounting
for valuation allowances on deferred taxes and acquired tax contingencies. The new guidance amends
the Codification guidance related to
31
accounting for income taxes such that adjustments made to
valuation allowances on deferred taxes and acquired tax contingencies associated with acquisitions
that closed prior to the effective date of this guidance would also apply its provisions.
In March 2008, the FASB issued new accounting guidance on disclosure requirements for
derivative instruments and hedging activities to enhance the current disclosure framework. The
additional disclosures require information about how our interest rate swap agreements and hedging
activities affect our financial position, financial performance, and cash flows. We adopted the
new guidance on January 1, 2009 and have included the applicable disclosures in Notes 6 and 7 in
our Notes to Condensed, Consolidated Financial Statements. The adoption did not have a material
impact on our consolidated financial statements.
In April 2008, the FASB issued new accounting guidance on the determination of the useful life
of intangible assets. The guidance was designed to improve the consistency between the useful life
of a recognized intangible asset under previous guidance related to goodwill and other intangible
assets and the period of expected cash flows used to measure the fair value of the asset under
business combinations guidance, and other GAAP. We adopted the new guidance on January 1, 2009.
The adoption did not have a material impact on our consolidated financial statements.
In April 2009, the FASB issued new accounting guidance for disclosures about fair value of
financial instruments, which amends the previous guidance to require disclosures about fair value
of financial instruments for interim reporting periods of publicly traded companies as well as in
annual financial statements. The new guidance also amends the previous guidance related to
interim financial reporting to require those disclosures in summarized financial information at
interim reporting periods. The new guidance is effective for interim periods ending after June
15, 2009. We early adopted the provisions and all other related guidance for the quarter ended
March 31, 2009.
In April 2009, the FASB issued new guidance regarding accounting for assets acquired and
liabilities assumed in a business combination that arise from contingencies. This guidance
requires recognition at fair value of such contingencies if the acquisition-date fair value can be
determined during the measurement period. This guidance became effective for us for contingent
assets and liabilities arising from business combinations with acquisition dates on or after
January 1, 2009. Our adoption of this guidance did not have a material impact on our consolidated
financial statements.
In May 2009, the FASB issued new accounting guidance related to subsequent events. The new
guidance establishes general standards of accounting for and disclosure of events that occur after
the balance sheet date but before financial statements are issued or are available to be issued.
It requires disclosure of the date through which subsequent events have been evaluated and whether
that date represents the date the financial statements were issued or were available to be issued.
We adopted this guidance for the quarter ended June 30, 2009. The adoption did not have a material
impact on our consolidated financial statements.
In June 2009, the FASB issued new guidance pertaining to variable interest entities. The new
guidance amends previous guidance to replace a quantitative analysis with a qualitative analysis of
interests in variable interest entities for the purpose of determining the primary beneficiary of a
variable interest entity. It also requires companies to more frequently assess whether they must
consolidate a variable interest entity. The new guidance will be effective for our company on
January 1, 2010. We are currently evaluating the impact on our consolidated financial statements;
however, we do not expect the adoption of this standard will have a material impact on our
consolidated financial statements.
In August 2009, the FASB issued Accounting Standards Update (ASU) 2009-5, Measuring
Liabilities at Fair Value. The ASU provides additional guidance in determining the fair value of
liabilities particularly in circumstances where a quoted price in an active market for an identical
liability is not readily available. It will be
effective for us for the quarter ending December 31, 2009. We do not expect the adoption will
have a material impact on our consolidated financial statements.
In October 2009, the FASB issued ASU 2009-13, Multiple-Deliverable Revenue Arrangements. This
ASU amends existing GAAP for separating consideration in multiple-deliverable arrangements and
establishes a selling price hierarchy for determining the selling price of a deliverable.
Additionally, it eliminates the residual method of allocation, requires consideration be allocated
using the relative selling price method and expands required disclosures related to a vendors
multiple-deliverable revenue arrangements. This ASU is effective prospectively for revenue
arrangements entered into or materially modified in fiscal years beginning on or after June 15,
2010, with
32
early adoption permitted. The adoption of this ASU will have a material impact on our
Medical Technology business segment. We expect that the implementation of the requirements of this
standard will result in the more timely recognition of revenue. We expect to early adopt the new
requirements no later than January 1, 2010.
In October 2009, the FASB issued ASU 2009-14, Certain Revenue Arrangements that Include
Software Elements. This ASU provides additional guidance on determining which software, if any,
relating to a tangible product should be excluded from the scope of software revenue guidance.
Additionally, it provides guidance on how to allocate consideration to deliverables in arrangements
that include both tangible products and software. It is effective prospectively for revenue
arrangements entered into or materially modified in fiscal years beginning on or after June 15,
2010, with early adoption permitted. We expect that upon adoption of this new guidance we will no
longer be governed by the previous accounting standard related to software accounting. Instead, as
mentioned above, we will now be governed by ASU 2009-13. In conjunction with the early adoption of
ASU 2009-13 as mentioned previously, we will also early adopt this ASU.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
At September 30, 2009, we had borrowings of $518.2 million under our senior credit facility
with fluctuating interest rates based on market benchmarks such as LIBOR. For our variable-rate
debt, changes in interest rates generally do not affect the fair market value, but do impact
earnings and cash flow. To reduce the risk of increasing interest rates, we entered into the
following interest rate swap agreements:
|
|
|
|
|
|
|
Interest Rate Swap Agreements |
Fixed interest rate |
|
5.34% |
|
2.64% |
Notional amount (in millions) |
|
$100.0 |
|
$100.0 |
Effective date |
|
6/11/2007 |
|
2/12/2008 |
Expiration date |
|
12/31/2009 |
|
2/26/2010 |
Counterparty |
|
Goldman Sachs |
|
Wells Fargo |
Qualifies for hedge accounting |
|
Yes |
|
Yes |
These interest rate swap agreements have the effect of reducing the amount of our debt exposed
to variable interest rates. For every 1.0% increase in LIBOR we will pay an additional $4.5
million in pre-tax interest expense on an annualized basis for the unhedged portion of our
senior-term notes. Conversely for every 1.0% decrease in LIBOR we will save $4.5 million in
pre-tax interest expense on an annualized basis. This represents an increase of $1.8 million in
both additional interest payments and interest savings, in comparison to our estimate included in
Item 7A of our 2008 Annual Report on Form 10-K, due to the expiration of all of our swaps in 2009
and 2010.
In the future, we may enter into additional interest rate strategies. However, we have not
yet determined what those strategies may be or their possible impact.
ITEM 4. CONTROLS AND PROCEDURES
We carried out an evaluation required by the Exchange Act, under the supervision and with the
participation of our principal executive officer and principal financial officer, of the
effectiveness of the design and operation of our
disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, as of
the end of the period covered by this report. Based on this evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were
effective to provide reasonable assurance that information required to be disclosed by us in the
reports that we file or submit under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in the SECs rules and forms and to provide reasonable
assurance that such information is accumulated and communicated to our management, including our
principal executive officer and principal financial officer, as appropriate to allow timely
decisions regarding required disclosure.
During our most recent fiscal quarter, there were no changes in our internal control over
financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange
Act) that has materially affected, or is reasonably likely to materially affect, our internal
control over financial reporting.
Our disclosure controls and procedures are designed to provide reasonable assurance of
achieving their objectives as specified above. Management does not expect, however, that our
disclosure controls and procedures will prevent or detect all error and fraud. Any control system,
no matter how well designed and operated, is based
33
upon certain assumptions and can provide only
reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of
controls can provide absolute assurance that misstatements due to error or fraud will not occur, or
that all control issues and instances of fraud, if any, within the company have been detected.
PART
II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are not subject to any legal proceedings other than ordinarily routine litigation
incidental to the conduct of our business.
ITEM 1A. RISK FACTORS
There have been no material changes in our risk factors from those disclosed in our 2008
Annual Report on Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
ITEM 5. OTHER INFORMATION
None
ITEM 6. EXHIBITS
|
|
|
31.1
|
|
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002. |
|
|
|
31.2
|
|
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002. |
|
|
|
32.1
|
|
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002. |
34
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized on November 6, 2009.
|
|
|
|
|
|
|
|
Date: November 6, 2009 |
By: |
/s/ Tomas W. Fuller
|
|
|
|
Tomas W. Fuller |
|
|
|
Chief Financial Officer |
|
|
35
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
31.1
|
|
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of
2002. |
|
|
|
31.2
|
|
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of
2002. |
|
|
|
32.1
|
|
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002. |
36